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ABSTRACT 
Grainyhead-like 2 Sensitizes Cells to Natural Killer Cell Cytotoxicity and Promotes the Interferon 
Response 
Ian Philip MacFawn 
Our research determined that the epithelial master transcription factor Grainyhead-like 
2 (GRHL2) promotes sensitivity to Natural Killer (NK) cell-mediated killing, and modulates the 
interferon I (IFN-I) response of epithelial cells. Immune surveillance by NK cells constitutes a 
major selective pressure for circulating tumor cells. Epithelial (GRHL2-expressing) cells exhibited 
significantly higher rates of NK conjugation, a crucial step in direct cell-mediated cytotoxicity. 
Mechanistically, GRHL2 upregulates expression of intercellular adhesion molecule 1 (ICAM-1), a 
cell surface molecule critical for NK to target cell synaptogenesis. GRHL2 epigenetically 
regulates gene expression, and we found that GRHL2 mutant proteins unable to interact with 
the epigenetic modifiers p300 or KMT2C/D exhibited altered NK sensitivity, and ICAM-1 
expression was lost. In summary, the epithelial state, enforced by GRHL2, kept these cells 
susceptible to NK-mediated cytolysis. Further, our data suggest GRHL2 critically promotes IFN I 
production in response to a double strand RNA mimetic. The results from these experiments 
identify novel roles for GRHL2 in maintaining the relationship between epithelial cells and the 
innate and adaptive arms of the immune system. 
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Chapter I: GRHL2 sensitizes cell to Natural Killer cell cytotoxicity through epigenetic 
mechanisms. 
 
 
Chapter I: Introduction 
Perturbation of genetic homeostasis in epithelial cells is a significant driver of 
tumorigenesis; over 90% of cancers are classified as “carcinoma”, which arise from epithelial 
origin. Epithelial cells are one of many final products of a long and tightly regulated process of 
differentiation that begins in embryonic stem cells during early mammalian development. In 
order to limit the self-renewing, pluripotent characteristics of embryonic stem cells, master 
transcription factors must be turned on, or off, in a concerted manner in order to gradually 
narrow the potential lineage-specific gene expression programs of different subsets of the 
rapidly proliferating embryo. Thus, the “terminally” differentiated epithelial cell which 
comprises various tissue across the body is locked into its identity by the concerted influence of 
epithelial master transcription factors which promote the expression of epithelial genes (A. F. 
Chen et al., 2018; Soares & Zhou, 2018), and antagonize the expression and activity of various 
stemness or mesenchymal master transcription factors. A great body of scientific literature has 
illustrated the oncogenic characteristics that arise from imbalance of epithelial-mesenchymal 
transcriptional control (Nieto, Huang, Jackson, & Thiery, 2016; Ribatti, Tamma, & Annese, 
2020). These include resistance to chemotherapeutics, increased invasion and motility, anoikis- 
resistance, phenotypic plasticity, aberrant immune response, metabolic reprogramming, and 
more. Hence, promoting the epithelial “default” state discourages some types of oncogenic 
progression and represents a lynchpin for understanding tumor biology (Frisch, 1997). 
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Grainyhead-like 2 (GRHL2) is considered an epithelial master transcription factor. Acting 
as a pioneer transcription factor, GRHL2 localizes to genomic loci and binds closed chromatin 
regions, subsequently recruiting chromatin remodeling enzymes in order to alter histone 
modifications, thereby loosening repressive chromatin and providing topography permissive for 
transcription factor binding (Jacobs et al., 2018; Reese, Harrison, & Alarid, 2019). Many 
canonical epithelial genes contain GRHL2 binding sites in their regulatory regions including 
CDH1, ELF3, OVOL2, RAB25, p63, CLDN4 (Frisch, Farris, & Pifer, 2017) . Pertaining to epigenetic 
regulation, GRHL2 has, at least, a DNA-binding region, a region which inhibits the histone 
acetyltransferase p300 (AA’s 425-437) and a direct interaction with the lysine 
methyltransferases KMT2C and KMT2D (AA’s 32-33) (Diagram 1) (MacFawn et al., 2019; Pifer et 
al., 2016). GRHL2 plays an indispensable role in early development by overseeing the human 
embryonic stem cell (hESC) to epiblast-like cell transition. During this time, GRHL2 becomes 
active, assumes control of target enhancers, and potentiates epithelial gene expression as the 
hESC transitions away from pluripotency towards a more differentiated “epiblast-like cell”: an 
early cell state that gives rise to subsequent epithelial cell lineages (A. F. Chen et al., 2018). 
The gene was originally described in Drosophila melanogaster: descriptively termed 
“Grainyhead’ following observations of a granular, sclerotic head phenotype in Grainyhead 
mutant flies. These flies also exhibited altered epidermal barrier formation and wound 
response, as well as an inability to properly control developmental genes normally manifested 
through promoter binding of ultrabithorax (ubx), engrailed, dopa carboxylase (Ddc) and the D. 
melanogaster E-cadherin homologue shotgun (Dynlacht, Attardi, Admon, Freeman, & Tjian, 
1989). D. melanogaster Grainyhead protein expression is temporally- and spatially-restricted to 
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ectoderm lineages during development, with detectable expression in epidermis, central 
nervous system (CNS), and gut (Bray, Burke, Brown, & Hirsh, 1989). Subsequent identification 
of the mammalian homologues revealed a family of “Grainyhead-like” genes: GRHL1, GRHL2 
and GRHL3. These three genes code for structurally similar proteins with a conserved N- 
terminal transactivation domain, a p53-like DNA-binding domain, and a C-terminal dimerization 
domain, however the functional roles of these proteins are diverse and mostly non-redundant 
(Frisch et al., 2017). 
 
 
 
Diagram 1. GRHL2 Protein Domain Map: 
TAD: Transactivation domain 
DBD: DNA-binding domain 
DD: Dimerization domain 
PID: p300 inhibiting region (Pifer et al., 2016) 
EDAA KMT2C/KMT2D interaction region (MacFawn et al., 2019) 
 
 
Owing to its prolific and widespread support of epithelial gene expression, 
downregulation or knockout of GRHL2 by various endogenous or ectopic methods is 
consequential for a wide variety of cellular characteristics and functions. In mice, GRHL2-/- mice 
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exhibit insufficient neural tube closure, epidermal defects and epithelial migration problems 
causing embryonic lethality at day E11.5 (Boglev et al., 2011; Ray & Niswander, 2016). GRHL2 
also regulates epithelial cells of the lungs, with expression in luminal and basal p63+/KRT5+ 
epithelium, while also forming a positive feedback loop with Nkx2-1 in alveolar type II cells, 
disruption of which leads to flattening and loss of cuboidal cell shape (Varma et al., 2012). 
GRHL2 was subsequently shown to orchestrate epithelial morphogenesis, polarity, and 
differentiation of basal stem cells in models of airway mucociliary epithelium (Gao, Bali, 
Randell, & Hogan, 2015). Kidney development and tubulogenesis are also impacted by loss of 
GRHL2, causing reduced collecting duct luminal expansion, reduced epithelial barrier integrity 
and rescue of tubulogenesis, respectively (Aue et al., 2015; Pifer et al., 2016). 
In addition to its integral role in specific tissue and organ development, GRHL2 
modulation has implications in cancer. The specific roles of Grainyhead-like proteins in cancer 
have been reviewed extensively (Frisch et al., 2017; He et al., 2020; Kotarba, Taracha- 
Wisniewska, & Wilanowski, 2020; Reese et al., 2019). Low GRHL2 expression, according to IHC, 
in a subset of breast cancer cells correlates with worse prognosis and lymph node metastasis, 
however, GRHL2 can also increase proliferation in breast cancer cell lines (Werner et al., 2013). 
Further, it was found that GRHL2 expression is absent in metastatic, “basal B” type breast 
cancer cell lines MDA-MB-231 and BT-549 cells, while in other breast cancer cell lines GRHL2 
was found to positively regulate erbb3 expression: a family member of erbb2 linked with poor 
outcomes in breast cancer (Werner et al., 2013). In colorectal cancer, GRHL2 knockdown 
increased metastasis in mouse models, via induction of EMT, but high expression was also 
positively associated with clinical stage and tumor size (Quan et al., 2015; Z. Yang, Wu, Chen, 
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Min, & Quan, 2019). In NSCLC, while high expression of GRHL2 correlates with worse prognosis, 
in vitro investigation found that while GRHL2 promotes proliferation and colony formation, it 
also inhibits metastatic attributes (Pan et al., 2017). GRHL2’s role in suppressing oncogenic EMT 
would point to a widespread function as a tumor suppressor, however, analysis of patient data 
accumulated by TCGA and other repositories, as well as in vitro and in vivo experiments 
exploring GRHL2’s effect on tumor progression reveals a highly context-dependent role for 
GRHL2. 
Tumor recurrence and metastasis remain the prevalent causes of death for cancer 
patients. Multiple mechanisms can lead to selection of resistant cells, including tumor immune- 
editing, persistence of drug-resistant subclones/cancer stem cells, phenotypic heterogeneity, 
and EMT (Dudas, Ladanyi, Ingruber, Steinbichler, & Riechelmann, 2020; F. Li, Tiede, Massagué, 
& Kang, 2007; Smith & Bhowmick, 2016). These can contribute to the selective process of 
tumor evolution, which winnows the composition of a tumor and can promote recurrence and 
metastatic spread to secondary sites in the body. Lately, much research emphasis has been 
directed towards understanding mechanisms that allow carcinoma cells to evade tumor 
immune surveillance and/or promote immunological tolerance. Incisive studies conducted by 
the Weinberg lab explored the spatial and cellular composition of the tumor immune 
microenvironment in a mouse adenocarcinoma MMTV-PyMT model (Dongre et al., 2017). 
Tumors from this model were isolated; their cells characterized and sorted based upon 
epithelial or mesenchymal features. Compared with epithelial (E-cadherin/EpCAMhi) cells, 
orthotopically re-introduction of mesenchymal cells (Vimentin/EpCAMlo) produced tumors 
containing more immunosuppressive CD25+ FOXP3+ Tregs and M2 polarized macrophages, 
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particularly in instances where the EMT TF Snail expression was high. The tumors arising from 
re-implanted epithelial cells contained more CD8+ T cells associated with effector function 
(GrzB, perf, IFN-γ) compared with the mesenchymal tumors which had numerically reduced 
CD8+ T cells that also exhibited higher PD-1. Interestingly, spatial analysis of co-injected 
epithelial and mesenchymal cells showed that the two cell types segregated in the resulting 
tumor, and that Arginase+ M2 macrophages preferentially associated with mesenchymal 
regions, while CD8+ T cells were found in proximity to epithelial regions (Dongre et al., 2017). 
These observations support the idea that tumor cells undergoing EMT may be more refractory 
to anti-tumor immunity, and may also create a sheltering immunosuppressive environment. 
Because of its ability to reinforce the epithelial state, thereby discouraging EMT, 
GRHL2’s ability to act in the capacity of a tumor suppressor has been previously investigated. 
GRHL2 antagonizes TGF-β-mediated signaling, reducing mammosphere formation and invasive 
capacity, while increasing BMP2 in HMLE cells. Further, Zeb1 has well-documented oncogenic 
effects in breast cancer and promotes plasticity and metastasis in pancreatic cancer; GRHL2 has 
been shown to repress Zeb1 in vitro (Cieply et al., 2012; Krebs et al., 2017; H.-T. Wu et al., 
2020). GRHL2 is also able to inhibit the metabolic switch towards oxidative phosphorylation 
often exhibited by cancer cells. Related to this, GRHL2 expression, in contrast to cells that have 
undergone EMT, suppresses the metabolic enzyme GLUD1, thereby maintaining intracellular 
ROS levels, helping cells to maintain sensitivity to anoikis (Farris et al., 2016). 
Regarding epigenetic regulation, GRHL2 inhibits the histone acetyltransferase (HAT) 
activity of p300, contextually, at mesenchymal gene regulatory regions. Re-expression of GRHL2 
in a mesenchymal subpopulation (MSP) (CD44hi/CD24lo) of HMLE cells causes repression of 
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various matrix metalloproteinase (MMPs), likely attributable to reduced p300-deposited 
H3K27ac at promoters, as experimentally observed with MMP1, MMP2 and MMP14 (Pifer et 
al., 2016). The inhibition of p300 HAT activity is notable; while this capability is also shared by 
adenoviral E1A protein, the vast majority of transcription factors (>400) associating with p300 
are thought to mainly use it as a coactivator, rather than inhibiting it. GRHL2 joins E1A-like 
inhibitor of differentiation (EID) proteins as unique inhibitors of p300 function (Pifer et al., 
2016). Expanding the mechanism of GRHL2’s transcriptional control, preliminary yeast two 
hybrid interaction data produced previously in our lab, and experiments conducted by other 
researchers, suggest that the two paralogous lysine methyltransferases 2C and D (KMT2C, 
KMT2D), also known as MLL3 and MLL2, could interact with GRHL2. KMT2C and KMT2D are 
members of the MLR subgroup of the KMT2 protein family. They are high molecular weight 
proteins (4915aa, 5537aa) and contain a catalytic SET domain for lysine methylation, their 
namesake, among other domains. KMT2C and KMT2D join a conglomeration of epigenetic 
regulatory proteins as part of the COMPASS complex (Complex of Proteins Associated with 
Set1) (Fagan & Dingwall, 2019). SET domain mutation is frequently observed in KMT2A and 
KMT2C, suggesting that stability of their lysine methyltransferase activity is consequential in 
tumor development (Weirich, Kudithipudi, Kycia, & Jeltsch, 2015). Indeed, KMT2C and KMT2D 
are two of the most commonly occurring mutated genes across all cancer types; to illustrate, 
KMT2C is found to be mutated in 8%-11% of breast cancer patients (Ellis et al., 2012; Fagan & 
Dingwall, 2019; Wang et al., 2011), with a reduction in mRNA levels in 43% of patients (Wang et 
al., 2011). In estrogen receptor positive (ER+) breast cancer KMT2C is specifically implicated in 
supporting the ER-collaborating pioneer transcription factor FOXA1. FOXA1 utilizes KMT2C’s 
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H3K4me1 (monomethylation) function to modify enhancer regions of target genes, permitting 
transcription. In this study, rapid immunoprecipitation mass spectroscopy of endogenous 
proteins (RIME) also revealed GRHL2 as a top predicted associator with KMT2C (Jozwik, 
Chernukhin, Serandour, Nagarajan, & Carroll, 2016). A direct interaction between KMT2C/D and 
GRHL2 was tested and well supported by data produced previously in our lab. Understanding 
the interplay between GRHL2 and these epigenetic interactors is important in understanding 
how it influences epithelial identity, as well as repressing or reversing EMT. By reinforcing 
epithelial gene expression programs, GRHL2 preserves particular functions and responses 
across multiple cellular systems with demonstrable in vitro tumor suppressive effects. 
The process of EMT is thought to be intertwined with the metastatic potential of many 
cancer types. Many barriers exist to reduce the likelihood of a cell’s breaking away from its 
primary tissue site which may lead to metastasis, however, induction of various degrees of 
mesenchymal transition can equip a cell with tools to overcome these barriers (Pastushenko & 
Blanpain, 2019). EMT can cause cells to become more motile and invasive, dissolve surrounding 
matrix and resist anoikis (Pearson, 2019) (Cieply et al., 2012). Entering the circulatory system 
constitutes another major selective pressure on newly departed circulating tumor cells (CTCs). 
The number of circulating tumor cells shed from a primary site vastly exceeds the number of 
metastatic lesions, underscoring the tremendous negative selective pressures levied on 
disseminating tumor cells (Massagué & Obenauf, 2016). 
Circulating immune cells, particularly Natural Killer (NK) cells, surveille cells and can 
effectively destroy most virally infected or transformed cells (Lopez-Soto, Gonzalez, Smyth, & 
Galluzzi, 2017). NK cells share a common precursor with, and are the most populous members 
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of, the Innate Lymphoid Cells (ILCs). This clade is defined by a lack of lineage markers (lin-) and 
absence of antigen receptor expression; nonetheless, NK cells develop cytotoxic effector 
function while the other phylogenetic branches of this group: ILC1, ILC2 and ILC3, do not, and 
are specialized cytokine producing cells (Artis & Spits, 2015). No exclusively definitive marker of 
NK cell identity has been discovered; they share an amalgamation of markers overlapping with 
other immune cell subsets of the innate and adaptive arms. Nonetheless, they can be divided 
into two general populations: a CD16+ CD56dim cytotoxic subset, and a CD16- CD56bright 
 
cytokine secreting subset (Poli et al., 2009). These two subsets represent the prevalent 
functions of NK cells: to rapidly engage and kill target cells (Granzyme B, Perforin.; FasLigand, 
Trail; Antibody Dependent Cell-Mediated Cytotoxicity), and to secrete various cytokines 
including IFN-γ, GM-CSF, TNF and other growth factors. NK cells are uniquely tailored to 
surveille cells that are under the insidious influence of viral infection or malignant 
transformation (Mancini & Vidal, 2020; M. G. Morvan & L. L. Lanier, 2016). To this end they 
express a variety of activating and inhibitory receptors; the prevailing net signal will dictate the 
NK cell’s response upon recognition of a possible target cell. In contrast to CD8+ T cell 
dependence upon target cell MHC Class I expression for their cell-mediated cytotoxicity, NK 
recognition of an MHC Class I molecule through Killer immunoglobulin receptor (KIR) or CD94- 
NKG2C receptors will inhibit killing; they are not antigen-restricted (Mancini & Vidal, 2020). This 
“missing self” strategy allows innate immunity to thresh out cells that have attempted to 
downregulate MHC Class I expression; a strategy exploited by malignant or virally infected cells. 
NK cells also critically require stimulation of activating receptors to engage their effector 
functions. These receptors (and their ligands) include: DNAM1 (CD155), NKG2D/C (MICA,MICB, 
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RAET1E), NKp46 and FCγRIIIA (IgG/ADCC) (M. G. Morvan & L. L. Lanier, 2016). If an NK cell is 
triggered through receptor ligand binding, a formidable armament can be brought to bear 
against the offending cell including perforin and granzymes (perforin creates pores in the 
membrane through which the serine protease granzymes enter), FAS ligand and TRAIL. (Maelig 
G. Morvan & Lewis L. Lanier, 2016) 
 
Mechanistically, upon conjugation, NK cells form an immunological synapse with the 
target cell. NK integrins, namely lymphocyte functional antigen-1 (LFA-1) stabilize this physical 
association. Recognition of activating ligands displayed on the target cell induces receptor 
signaling in the NK cell that results in a high affinity conformation change in LFA-1 (Osman, 
Burshtyn, & Kane, 2007). LFA-1 binds to the intercellular adhesion molecule 1 (ICAM-1) 
displayed on target cells. LFA-1:ICAM-1 ligation initiates an NK signaling cascade that promotes 
synapse maturation and increased recruitment of LFA-1, talin-1 and F-actin to the conjugation 
region, also known as the cSMAC (central supra-molecular activating cluster) (Culley et al., 
2009; Vyas et al., 2001). The immunological synapse is tightly regulated, and, illustrating the 
specific sensitivity to NK ligands, in vitro co-culture of NK cells with both autologous and 
susceptible target cell lines revealed that instances where a coincident triple conjugation 
occurred (one NK conjugated to both an autologous and a susceptible cell) a cytolytic synapse 
was strongly favored towards the susceptible cell, while the autologous cell was largely left 
alone (Vyas et al., 2001). Successful initiation of a cytolytic immune synapse results in 
localization of cytotoxic vesicles containing perforin and Granzyme B that are maintained in a 
neutralized state by electrostatic interactions with the heparin sulfate proteoglycan Serglycin 
(S. M. Raja, Metkar, S. S., Honing, S., Wang, B., Russin, W.A., Pipalia, N.H., Menaa, C., Beling, M., 
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Cao, X., Dressel, R., Froelich, C.J., 2005; S. M. Raja et al., 2002). Serglycin has been implicated in 
other non-immune cells as well, with documented tumorigenic roles pertaining to inflammation 
and EMT (Bouris et al., 2018; Manou, Karamanos, & Theocharis, 2020). The cytotoxic vesicles 
arrive at the immune synapse and are thought to exit the NK cell through permissible regions of 
f-actin meshwork and are exchanged into the target cells (Vyas et al., 2001). 
Thus, ICAM-1 expression is a critical surface molecule mediating NK cytotoxicity. Its 
regulation can dictate the extent to which NK cells can effectively conduct immunosurveillance. 
In acute myeloid leukemia (AML), GSK3β activation in NK cells can render them less potent. Ex 
vivo treatment of human donor NK cells with a GSK3β inhibitor rescued cytotoxic activity in an 
LFA-1:ICAM-1 dependent manner. GSK3β inhibition not only upregulated LFA-1 expression on 
NK cells, but also lead to increased ICAM-1 expression on target cells in response to increased 
TNFα secretion by the NK cells. In this model, perforin and granzyme B levels only changed 
modestly, underscoring the significance of ICAM-1 expression in facilitating NK killing 
(Parameswaran et al., 2016). ICAM-1 is also upregulated in response to radiation in numerous 
cancer cell lines, facilitating NK killing relative to unirradiated controls. Of note, NK cells also 
secreted significantly higher levels of IFN-γ when co-cultured with irradiated HL60 and T47D 
compared with unirradiated co-culture. (Jeong et al., 2018) 
Natural Killer cells are major contributors to “natural cytotoxicity”, an appreciated 
predictor of antitumor immunity. A large cohort study conducted over 11 years found that 
healthy donors whose peripheral blood lymphocytes measured higher, baseline cytotoxic 
activity had lower cancer incidence over time (K. Imai, Matsuyama, Miyake, Suga, & Nakachi, 
2000). Older studies conducted on patients with familial melanoma and familial breast cancer 
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indicated that these patients were more likely to have lower peripheral blood cytotoxic activity 
against cultured target cells, implicating cytotoxic activity in cancer incidence (Hersey, Edwards, 
Honeyman, & McCarthy, 1979; Strayer, Carter, & Brodsky, 1986). Further evidence in mouse 
models suggest that NK cells likely influence the dynamics of primary tumor establishment. Rag- 
/- (lacking T and B cell lineage) deficient mice were additionally depleted of NK cells via 
knockout of Il2-receptor gamma. Rag-/- mice lacking NKs exhibited increased occurrence of 
methylcholanthrene initiated sarcomas: an effect attributed to lack of NK-derived IFN-γ 
stimulation of M1 macrophages, demonstrating a role for innate immunity during primary 
 
tumor development (O'Sullivan et al., 2012). Ablation of NK activating receptors DNAM1-/- or 
NKp46-/- causes development of tumors enriched for the respective ligands in sarcoma models 
(Elboim et al., 2010; Iguchi-Manaka et al., 2008). Further, voluntary exercise has been shown to 
increase NK infiltration and reduce tumor burden in mice through β-adrenergic activation of IL- 
 
6 responsive NK cells (Pedersen et al., 2016). 
 
NK-specific alterations in mouse tumor models have been especially informative in 
linking NK cells with metastasis. Deletion of Mcl2 in murine NK cell lineages removes NK cells 
from the circulation, resulting in dramatically enhanced metastases when challenged with low 
levels of B16-F10 melanoma cells (Sathe et al., 2014). In a colorectal carcinoma model, adoptive 
transfer of CD27lowKLRG1+ NK cells rescued T-bet deficient mice from lung metastasis (Malaisé 
et al., 2014). NKs engineered to express a constitutively active TGFBR1 (inhibiting NK function in 
part by downregulation of receptors and loss of cytotoxicity) exhibited reduced degranulation 
in the presence of target cells, while NK-specific ablation of TGFBR2 led to decreased lung 
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metastasis after injection of B16-F10 or RM-1 cancer cells (Viel et al., 2016). NK-mediated 
intravenous clearance of circulating mammary tumor cells was demonstrated in D2A1 
intravenously injected BALB/C mice which had been treated with anti-asialo-GM-1 antibody, 
these NK ablated mice exhibited 5.5x increased lung-localized D2A1 cells. Intriguingly, this 
model also showed that mice with a concurrent 4T1 subcutaneously implanted mammary 
tumor (which substantially increases systemic neutrophil numbers) mimicked the increased 
metastatic parameter seen in NK-depleted mice, suggesting that tumor-influenced neutrophil 
dynamics modulated NK activity (Spiegel et al., 2016). Similarly, utilizing NK1.1 antibody in a 
C56BL/6 mouse model lead to a 7x increase in lung-localized B16-F10 intravenously injected 
melanoma cells (Spiegel et al., 2016). The literature supports the ability of Natural Killer cells to 
inhibit metastasis, and influence primary tumor development through cytolytic effector 
functions, but also through interaction or synergy with other immune cells. 
EMT has been investigated as a possible mechanism conferring resistance to immune 
effector-mediated cytotoxicity. Due to the gradient, non-binary nature of EMT, as well as the 
multiple mechanisms of immune effector cell killing, numerous avenues of EMT-derived 
resistance and sensitivity have been reported (Lopez-Soto et al., 2013; Terry, Buart, et al., 
2017). A NSCLC primary cell line model found that that subpopulations of cells that underwent 
EMT in response to hypoxia were more resistant to both cytotoxic T lymphocyte (CTL)- and 
NK92-mediated killing relative to cells that remained epithelial under hypoxia. Although 
conjugation remained similar between the epi./mes. subsets, the mesenchymal cells exhibited 
marks of reduced immunological synapse function. Sensitivity was rescued by siRNA’s targeting 
EMT transcription factors Zeb1, Zeb2, Snai1 and Snai2, or pharmacologic inhibition of 
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mesenchymal cell TGF-β production (Terry, Buart, et al., 2017). Mcf7 breast carcinoma cells 
induced to an EMT state via TNF-α exposure (Mcf7-2101) or ectopic Snail (Mcf7-SNAI1) cells 
exhibited increased resistance to CTL lysis. This resistance was linked with EMT-induced 
autophagy, as knockdown of beclin1 restored CTL lysis. (Akalay et al., 2013). Supporting a role 
for autophagy in NK sensitivity, NSCLC models, independent of EMT, demonstrated that 
inhibiting autophagy using RocA (inhibiting ULK1 expression among other things) caused a 
synergistic effect to promote NK killing in an in vivo mouse tumor model. Autophagy inhibition 
led to increased Granzyme B concentration in target cells (Yao et al., 2018). EMT’d derivatives 
of MCF7, as well as MDA-MB-231 cells exhibited significantly upregulated immunosuppressive 
programmed death-ligand 1 (PD-L1) expression, attributed to the EMT transcription factor 
Zeb1. Increased resistance to CTL lysis was attributed to PD-L1 expression, an effect that was 
independent of TGF-β expression in this model (Noman et al., 2017). As described above, NK- 
target conjugation and synaptogenesis requires concerted and sequential cytoskeletal 
arrangement and interaction. It is likely that the resultant altered cytoskeletal arrangement 
after EMT would augment NK conjugation and synapse formation to greater or lesser degrees 
(Terry, Savagner, et al., 2017). The ability of resistant breast cancer cell lines to effectively 
remodel actin at specific focal points enabled resistance to NK-mediated cytotoxicity in a CDC42 
or N-WASP dependent manner (Al Absi et al., 2018) 
Based upon these observations, it seemed plausible that Grainyhead-like 2 could play a 
role in maintaining proper sensitivity to anti-cancer immunity by inhibiting EMT. The central 
hypothesis of this chapter is as follows; through promotion of an epithelial default state, 
Grainyhead-like 2 will promote sensitivity to Natural Killer cell cytotoxicity. We employed 
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various cell culture models to test this hypothesis. We chose multiple cell lines that could be 
induced to exhibit either a mesenchymal or epithelial state through various means, including 
knockout or overexpression of GRHL2 (See Cell Lines Diagram in Material and Methods). The 
stable ectopic expression of GRHL2 in Ras-transformed human breast epithelial cells 
(Mcf10aneoT) that had been induced to undergo stable EMT after transient addition of TGF-β, 
the mesenchymal human fibrosarcoma cells (HT1080), and human mammary epithelial cells 
(HMLE) that can be selected for a CD44hi/CD24lo mesenchymal subpopulation (MSP). We also 
utilized cell lines induced to undergo an MET by alternative means; expression of adenoviral 
protein E1a, which inhibits p300 and induces MET (Frisch, 1994, 2001), and activation of the 
microRNA miR200C, which has also been noted to induce MET and repress immunosuppression 
(Howe, Cochrane, & Richer; Rogers et al., 2018). We explore sensitization of these cell lines to 
NK92mi cytotoxic attack, identify candidate molecules dictating sensitivity/resistance, and 
investigate GRHL2’s epigenetic influence on NK sensitivity. This research opens up exciting 
prospects implicating GRHL2 as an important mediator of the epithelial immune setpoint. 
Upcoming data in Chapter II will explore the breadth of GRHL2’s control of interferon signaling. 
These experiments could help to elucidate fundamental principles pertinent to the epithelial 
versus mesenchymal state as it impacts innate immunity and interferon signaling in anti-viral 
and anti-tumor immunity. To conclude, our data supports the hypothesis that Grainyhead-like 
2 safeguards the subordinate relationship of epithelial cells to anti-tumor immunity: a 
relationship that is frequently manipulated and deranged during tumor progression. 
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Diagram 2: The Significance of GRHL2 for Tumor Biology. Idea for figure adapted from 
(Sulaiman, Ab Mutalib, & Jamal, 2016), words and drawing inserted by I. MacFawn. 
 
 
 
Chapter I:  Results 
 
I.a. GRHL2 sensitizes cells to NK92 cytotoxicity 
 
In order to test the effect of the epithelial state on sensitivity to NK attack, we reverted 
mesenchymal cell lines to an epithelial state through induction of GRHL2, miR200C, or E1a 
protein. We retrovirally expressed GRHL2 in a CD44hiCD24lo -sorted mesenchymal 
subpopulation (MSP) of human mammary epithelial (HMLE) cells, as well as Mcf10aneoT cells 
that had undergone EMT in response to TGF-β, and HT1080 fibrosarcoma cells (Cieply et al., 
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2012; Farris et al., 2016; Pifer et al., 2016). Additionally, we expressed an inducible miR200C 
microRNA in BT549 breast cancer cells (Howe et al.; Rogers et al., 2018), and adenovirus E1a 
protein in HT1080 cells (Frisch, 1994, 2001; Pifer et al., 2016) to induce MET. The isogenic 
epithelial and mesenchymal variants of each cell line served as target cells, while the 
immortalized human NK92-MI cells were used as the immune effector cell. Using NK cells as our 
immune effector cell was appropriate because of their documented, efficient anti-metastatic 
function, and, in contrast to CD8+ T-cells, specifically target cells that lack MHC Class I surface 
expression. Additionally, NK-92 MI cells, in contrast to endogenous NKs, are no longer inhibited 
by MHC Class I expression due to deletion of Killer cell immunoglobulin receptor (KIR), and have 
an IL-2 transgene (Klingemann, Boissel, & Toneguzzo, 2016). Because of these subtleties, the 
NK92-MI cell line allow us to use one broadly applicable effector population to test sensitivity 
to cytotoxic killing across a variety of non-syngeneic target cells. 
Our preferred method of assessing viability during NK assays was through stable ectopic 
expression of a “Nano-luciferase” construct in target cells, which allows for quantification of 
cell death as a luminescence signal (Rossignol, Bonnaudet, Clemenceau, Vie, & Bretaudeau, 
2017). Some assays were also conducted using a dual staining method, or using PrestoBlue 
viability reagent. We observed markedly increased sensitivity to NK attack in our epithelial 
derivatives compared to mesenchymal cells when adherent cells were co-cultured with NK cells 
over a time course ranging from 4-24hrs (Fig 1.a) . Normalized luminescence was used as a 
measure of Nano-luc released into supernatant resulting from membrane degradation in dying 
target cells. NK assays conducted in suspension, with non-adherent target cells, perhaps better 
mimicking cellular interactions during metastatic dissemination, also yielded similar results (Fig 
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1.b). To expand upon this finding, we also tested HT1080 fibrosarcoma and BT549 breast cancer 
cells induced to undergo MET by alternative pathways and found that they, too, exhibited 
increased sensitivity to NK attack when we expressed adenoviral E1a (inhibits HAT p300) and 
miR200C (MET inducer), respectively (Frisch, 2001; Howe et al.). These data support our 
hypothesis that sensitivity to Natural Killer cells is a feature of the epithelial state, and is 
consequentially altered by EMT. 
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Fig 1. GRHL2 sensitizes cells to NK92 cytotoxicity. A.) Mcf10aneoT+GRHL2/sgGRHL2, 
Mcf10aneoT+TGF-β+GRHL2/mxs (“NTM”), HT1080+GRHL2/mxs, and HMLE/HMLE-MSP cells 
were plated at equal density in at least biological duplicate. When cells were ~70% confluent, 
NK92mi cells were added at 2:1-5:1 ratios and incubated until significant death was observed. 
B.) Target cells were suspended and mixed with NK92mi cells and resuspended periodically 
throughout the Suspension NK assay. C.) Additional methods of MET were utilized: i.) 
doxycycline inducible miR200C induced MET, dox was withdrawn prior to NK assay, ii.) a stable 
E1a adenoviral construct induces MET in HT1080, and iii.) an EMT’d derivative of Mcf7. 
%Viability was measured as [sample (X) lum. Signal] / [avg NO NK replicates lum. signal]. P- 
values calculated using Student’s Two-tailed T test.B.) Suspension NK assays involved 
trypsinizing, counting and suspending target cells at equal densities in microfuge tubes. NK92mi 
cells were added at 3:1 ratio. At timepoints, an aliquot was taken from the microfuge tube, 
mixed with Nano-glo complete reagent and luminescence value was read on platereader. These 
samples were blanked against a NO NK anoikis value, then normalized to a lysed NO NK sample 
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to calculate % Death. Assay Details: A1: Duplicate, 12/24hr time points. A2: Duplicate A3: 
Duplicate, 24hr timepoint. A4: Quadruplicate. B1: Triplicate. B2: Duplicate. C1: Quadruplicate. 
C3: Duplicate. 
I.b. The effect of Inhibitory/Activating NK Ligand 
Expression and Fadd knockdown on NK Killing 
We examined multiple hypotheses that could 
account for the increased sensitivity of epithelial cells to 
NK attack. We checked a previously generated RNAseq 
dataset comparing HMLE derivaties (Farris et al., 2016) for 
classical activating or inhibiting NK cell ligands, as well as 
adhesion molecules. We did not find any dramatic 
differential expression of NK ligands or receptors between 
mesenchymal and epithelial cells, though some were 
altered over 2-fold (Table 1). NK cells kill target cells via 
two direct mechanisms: delivery of perforin/granzyme B 
through an immune synapse, and/or cell surface 
expression of death ligands Fas and TRAIL. To distinguish 
between the method of killing in our system, we used an 
siRNA against Fadd; a critical adaptor protein that relays 
the death receptor ligand-binding signal to pro-caspases 8 
and 10, thereby initiating apoptosis. We knocked down Fadd in Mcf7, and Mcf10a cells, verified 
knockdown via western blot (Fig 2a), then conducted NK assays on these cell lines. Knockdown 
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of Fadd did not rescue cells from NK-mediated death (Fig 2b), suggesting that in our system, the 
NK cells were killing through a different mechanism, likely perforin/granzyme B delivery 
through the immune synapse. This insight allowed us to target a narrower range of possible 
molecules and mechanisms involved in epithelial sensitization to NK attack in our system. 
 
 
Figure 2. GRHL2’s promotion of NK sensitivity is independent of death receptor signaling. Fadd 
was knocked out by siRNA in Mcf10a and Mcf7 cells. A.) Western blot indicates siRNA mediated 
knockdown of Fadd. B.-D.) siFadd Mcf7 and Mcf10a cell lines did not exhibit increased resistance 
to NK92mi killing in NK assays. NK assays conducted in duplicate. 
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I.c. The effect of epithelial versus mesenchymal ECM on NK92 killing. 
 
One major difference between epithelial and EMT’d cells is the amount and type of 
factors they secrete to develop extracellular matrix (ECM). Cells have a close relationship with 
underlying matrix and attach to these deposited factors through integrins, influencing 
intracellular signaling. Matrix composition or stiffness can change cytoskeletal dynamics and 
even induce EMT (Wei et al., 2015). We tested the effects of the specific matrix the cells were 
plated on by conducting matrix switch Granzyme B and NK assays. We separately plated 
epithelial and mesenchymal derivatives of a cell line and allowed the cells to grow to 
confluence. Using ammonium hydroxide (NH3O3), we lysed the cells but retained their secreted 
matrix. We then plated sub-confluent numbers of epithelial cells on the mesenchymal matrix 
and vice versa. Interestingly, we found that in some cases, the epithelial matrix sensitized the 
mesenchymal cell line to Natural killer cell cytotoxicity (Fig 3 a,b,c). This could imply that matrix 
components may regulate cell morphology and architecture, thereby effecting conjugation of 
immune effector cells to target cells. Despite numerous experiments and repeats, this effect 
was too often variable, despite reaching statistical significance in multiple experiments. This 
phenomenon warrants further investigation, but we decided to prioritize other, more tractable 
explanations for NK sensitization. 
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Figure 3. Matrix effects on NK sensitivity. A.) Mcf10aneoT+TGF-b+GRHL2/mxs were 
plated at equal density in duplicate or B.) triplicate. Cells were grown to confluence, lysed in 
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ammonium hydroxide, then wells were stringently washed and the opposite state cell 
(mes./epi.) was plated at equal densities onto the opposing matrix type. After attachment, 
NK92mi cells or C.) HT1080 (+GRHL2) or (+control vec) were plated in duplicate, as above. NK 
cells were added and viability was calculated after significant death was apparent. 
1.c. GRHL2 suppresses expression of the proteoglycan Serglycin 
 
We also explored the role of the chondroitin sulfate proteoglycan Serglycin (SRGN). 
 
Serglycin has been implicated in tumor malignancy and the establishment of a pro- 
inflammatory microenvironment (Bouris et al., 2018; Korpetinou et al., 2014). Interestingly, 
SRGN also contains a protease resistant core structure which is utilized by immune cells, 
notably NKs, to neutralize proteolytic enzymes within secretory vesicles containing perforin and 
Granzyme B (S. M. Raja, Metkar, S. S., Honing, S., Wang, B., Russin, W.A., Pipalia, N.H., Menaa, 
C., Beling, M., Cao, X., Dressel, R., Froelich, C.J., 2005). In Mcf10aneoT and HT1080, mRNA 
measured by qRT-PCR indicated SRGN is strongly repressed by GRHL2 (Fig. 4 a,b). RNAseq 
datasets agreed with these findings; Serglycin is upregulated 205-fold upon GRHL2 knockout in 
a Mcf10aneoT (Fig. 4, c). We thought that Serglycin expression may be a means for EMT’d cells 
to neutralize the cytotoxic molecules of immune effector cells (perforin, granzyme B). We 
packaged a secreted serglycin construct into pMXS-ires-Blast vector and retrovirally 
overexpressed it in epithelial Mcf10aneoT+GRHL2, Mcf10a and HT1080+GRHL2 cells. We also 
harvested conditioned media from mesenchymal cells and conducted NK assays in the presence 
of secreted media, after verifying the presence of SRGN by Western Blot. Despite the high 
expression levels of this protective proteoglycan, we did not see significant protective effect of 
SRGN overexpression or conditioned media as measured by cell viability during NK attack or 
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treatment with recombinant Granzyme B and streptolysin (a pore-forming enzyme that 
functions analogously to perforin). Mcf10aneoT+TGF-b+GRHL2 epithelial cells exhibited a non- 
statistically significant effect upon SRGN overexpression, while HT1080+GRHL2 cells showed a 
large, but not statistically significant protective effect of +SRGN C.M. when measured for 
sensitivity to Granzyme B (Fig 4. c). It is possible that the disproportionate expression of 
Serglycin between epithelial and mesenchymal cells in our models contributes to other pro- 
tumorigenic processes, but it appears to have a modest or negligible impact on direct immune 
cell-mediated killing in our models. 
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Figure 4. GRHL2 represses Serglycin expression. A.) qPCR analysis of Serglycin mRNA levels in 
Mcf10aneoT+TGF-β +GRHL2, Mcf10aneoT+TGF-β+sgGRHL2 and HT1080, HT1080+GRHL2 
normalized to GAPDH. B.) RNAseq mRNA expression levels of Serglycin in Mcf10aneoT, 
Mcf10aneoT+sgGRHL2. C.) NK killing assays were conducted on Mcf10aneoT+GRHL2 cells with 
or without stable overexpression of SRGN, assays conducted in duplicate. Similarly, Granzyme B 
sensitivity was measured on HT1080 cells (+/-GRHL2) in the presence or absence of +SRGN 
conditioned media, assays conducted in triplicate. Statistical analysis was conducted using a 
Student’s Two Tailed T test. 
 
 
 
I.d. GRHL2 suppresses autophagy in HT1080 cells 
 
Reports suggest that upregulation of autophagy can modulate target cell sensitivity to 
immune attack (Akalay et al., 2013). Breast cancer cells that upregulate autophagy become 
more sensitive to NK-mediated killing through sequestration of anti-apoptotic proteins in the 
lysosome (Akalay et al., 2013) (Yao et al., 2018) . Conversely, Renal cell carcinoma cells that 
upregulated autophagy upon interaction with NK cells displayed better survival and lower 
intracellular Granzyme B levels (Messai et al., 2014). We hypothesized that differential 
autophagy could be a mechanism for resistance to NK attack. We expressed a tandem GFP/RFP- 
LCIII (tfLCIII-GFP) vector in our HT1080/HT1080+GRHL2 cells. Cells were first Glucose-starved in 
HBSS for 2hrs, then incubated in 100nM Bafilomycin for 2hrs. Cells were fixed and autophagic 
flux was calculated by subtracting the LCIII punctae in (-Baf) cells from the average LCIII punctae 
in (+Baf) cells. Because Bafilomycin halts fusion of the autophagosome and lysosome, the 
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difference between +/- Bafilomycin represents autophagic flux. We found that expression of 
GRHL2 significantly reduced autophagic flux in HT1080 cells (Fig 5. a,b). However, successful 
knockdown of Beclin, a key autophagy protein, by siRNA in HT1080 (HTM2) and Mcf10aneoT 
(NTM2) cells, caused statistically non-significant changes to NK-sensitivity (Fig 5. c,d,e,f). Our 
data suggests that EMT modulation can have effects on autophagy rates, but in our models, this 
did not seem to contribute significantly to NK sensitivity. 
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Figure 5. GRHL2 regulates autophagy. A.) After expression of a fluorescent LCIII plasmid (tcfLCIII- 
GFP), HT1080+vec (“HTM2”) or HT1080+GRHL2 (“HTG2”) cells or Mcf10aneoT+TGF-β+vec 
(“NTM”) or Mcf10aneoT+TGF-β+GRHL2 (“NTG2”) were glucose starved in HBSS for 2hrs, then 
incubated in 100nM Bafilomycin for 2hrs. Cells were fixed, then number of punctae in (-) Bafilo 
was subtracted from punctae in (+) bafilo. to calculate autophagic flux on a fluorescence 
microscope. B.) Quantification of images. C.) To inhibit autophagy, we transfected Beclin siRNA 
to knockdown protein levels in NTM and HTM cells. D-F.) NK assays were conducted on Beclin 
knockdown cells as described previously. Cells were plated in a minimum of biological duplicate. 
Statistical analysis was conducted using Student’s Two Tailed T test. Assay details: 5D: 
Triplicate. 5E: duplicate. 5F: Triplicate. 
 
 
 
I.e GRHL2 promotes NK92/target cell conjugation through upregulation of ICAM-1 
 
Differences in NK assay dynamics, visually apparent under low power magnification, 
suggested that immune cell synaptogenesis could be augmented by epithelial state. The 
immune synapse is an essential part of direct NK cell-mediated cytotoxicity. NK cells approach, 
and physically conjugate with target cells. If the balance of activating versus inhibitory ligands 
is permissive, they initiate a complex polarization and rearrangement of the cell membrane, 
termed the “immune synapse”, towards the target cell, through which they release the 
contents of granular cytotoxic vesicles. These granules include Perforin, which creates small 
pores in the target cell membrane allowing other granules, like Granzyme A and B: serine 
proteases involved in initiator and executioner caspase activation and mitochondrial ROS 
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deregulation and DNA damage induction, respectively, to pass into the target cell (Lieberman, 
2010) (Afonina, Cullen, & Martin, 2010). Upon incubation with NK cells, we noticed that 
epithelial cells seemed to attract more NK cells, causing them to cluster and stick to the target 
cells. These NK cells remained bound to epithelial cells through multiple washings of the cells, 
suggesting strong and stable physical connection. 
To quantify the conjugation of NK92 to target cells we separately stained target cells 
with CMFDA and NK92mi cells with CMPTX allowing fluorescent detection of different cell 
populations. We washed the populations of cells numerous times, then conducted NK assays 
using the stained cells. At timepoints, we gently washed the wells with sPBS to removed 
unconjugated NK cells, then fixed the cells with paraformaldehyde and imaged on an 
epifluorescence microscope. The ratio of NK to target cell (NK conjugation) was elevated in cells 
expressing GRHL2 compared with the mesenchymal derivative in both Mcf10aneoT+TGF- 
b+GRHL2 versus Mcf10aneoT+TGF-b and HMLE versus HMLE-MSP (Fig 6. a-c) 
The conjugation efficiency prompted us to re-assess the expression of adhesion 
molecules on target cells. Intercellular adhesion molecule 1 (ICAM-1) mRNA was upregulated by 
GRHL2 in HMLE, HT1080 and Mcf10aneoT (Fig 6. d). ICAM-1 is an interferon stimulated gene 
(ISG), and is strongly upregulated by the NK- and T cell-secreted cytokine interferon gamma 
(IFN-γ) (M. L. Dustin, Rothlein, Bhan, Dinarello, & Springer, 2011) (M. G. Morvan & L. L. Lanier, 
2016). ICAM-1 expression is an important mediator of the antiviral and anti-tumor immune 
response; its cell surface expression facilitates adhesion and conjugation of immune effector 
cells via formation of the immunological synapse through interaction with LFA-1 on immune 
cells (Michael L. Dustin, 2014). Western blot analysis supported the preferential expression of 
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ICAM-1 in cells expressing GRHL2 (Fig. 6 e,f). Further, we found that cells lacking GRHL2 
exhibited severely limited ICAM-1 protein expression in response to IFN-γ stimulation in vitro 
(Fig. 6 e,f). To test the dependence of NK sensitivity on ICAM-1 expression, we used an ICAM1 
monoclonal antibody to block ICAM-1 on the surface of target cells. HMLE and HT1080+GRHL2 
epithelial cells were pre-incubated with the α-ICAM-1 antibody, washed thoroughly to remove 
excess antibody, then subjected to NK92mi cells. Pre-blocking epithelial cells with ICAM-1 
antibody dramatically reduced NK92mi-mediated killing (Fig 6. g). We propose that ICAM-1 is 
maintained in epithelial cells by GRHL2 under basal conditions, and that GRHL2 could be an 
important regulator of the interferon response because treatment with IFN-γ for up to 16hrs 
had a comparatively limited effect on ICAM-1 mRNA and protein in the absence of GRHL2. 
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Figure 6. GRHL2 promotes NK-target conjugation via ICAM1 upregulation. A.) Mcf10aneoT+TGF- 
β+vec (“NTM”) or Mcf10aneoT+TGF-β+GRHL2 (“NTG2”) and HMLE or HMLE-MSP cells were 
evaluated for NK92mi conjugation occurrence. Target and NK cells were separately, transiently 
stained with either CMFDA or CMPTX. After washing, NK assays were conducted. At timepoints, 
wells were gently washed using HBSS to remove unattached NK cells and floating target cells. 
Remaining cells were visualized and quantified by fluorescence microscopy to produce NK:target 
cell ratio for all wells. B.) Quantification of images. NK92mi cells were stained red in the HMLE 
experiment, while NK92mi cells were stained red in the Mcf10aneot+TGF-β experiment. 
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Quantification: NTM= fields:4, target cells: 307; NTG2=fields:5, target cells:446; HMLE- 
MSP=fields:4, target cells: 1,874; HMLE=fields:4, target cells:2,108. Quantification of 
conjugation was calculated using a Student’s Two Tailed T test. C. Representative images from 
NK conjugation assays. D.) qRT-PCR quantification of ICAM-1 mRNA expression in NTM vs. 
NTG2, HT1080+mxs vs. HT1080+GRHL2, and HMLE-MSP vs. HMLE-MSP+GRHL2. E,F..) ICAM1 
 
mRNA and protein before and after stimulation with IFN-γ was measured in HT1080, 
HT1080+GRHL2 and Mcf10aneoT+TGF-β, Mcf10aneoT+TGF-β+GRHL2 by qPCR normalized to 
GAPDH. For western blots, cell lysates were made before and after treatment with recombinant 
IFN-γ and western blotted, probed using indicated antibody, and quantified after normalization 
to GAPDH. D.) HT1080+GRHL2 and HMLE cells were pre-coated with ICAM1 blocking antibody, 
washed, then subjected to NK assays. Statistical significance calculated using Student’s Two 
Tailed T test. Assay Details: G1: Duplicate. G2: Duplicate 
1.f. GRHL2 regulates NK sensitivity through epigenetic interactions. 
 
GRHL2 exerts influence over its target genes through interactions with epigenetic 
modifiers (Pifer et al., 2016). The lab had previously demonstrated that GRHL2 inhibits the 
histone acetyltransferase p300 as indicated by targeted loss of Histone 3 Lysine 27 acetylation 
(H3K27ac) at GRHL2-repressed genes, but not global H3K27ac loss (Pifer et al., 2016). Results 
from a Yeast 2 Hybrid screen previously conducted in the lab revealed that GRHL2 also likely 
interacted with the Histone 3 Lysine 4 mono-methylating enzymes KMT2C and KMT2D, whose 
interactions were previously thought to be most strongly implicated in nuclear receptor 
function (Gala et al., 2018). Abundance of H3K4me1 is a hallmark of active enhancer regions. 
Development of a GRHL2 non-interacting mutant termed “EDAA” (indicating loss of 
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interaction upon mutation of AA’s 32 and 33 from glutamine and aspartic acid to alanine and 
alanine) had previously been generated and validated in the lab (MacFawn et al., 2019). We 
also used the previously generated and validated p300-non inhibiting GRHL2 mutant termed 
Δ425-437 (Pifer et al., 2016). We separately expressed both mutants in the mesenchymal cell 
lines HT1080, HMLE-MSP and Mcf10aneoT+TGF-β. After validating mRNA expression and 
equivalent protein expression by western blot, we characterized the EDAA and Δ425-437 cell 
lines in 5 ways. 
[1.] Morphological analysis: both EDAA and Δ425-437 GRHL2 mutants showed 
reduced adoption of epithelial cell morphology compared with GRHL2 WT overexpression, 
which typically show a visible MET phenotype (Fig. 7, a). [2.] qRT-PCR of classic GRHL2- 
regulated epithelial target genes indicated the inability of either EDAA or Δ425-437 to induce 
mRNA expression above control in Mcf10aneoT+TGF-β cells (RAB25, CDH1, ESRP1, OVOL2, 
TP63, CLDN4). (Fig. 7, b) [3.] Both mutants showed altered sensitivity to anoikis compared with 
GRHL2 WT (Fig. 7,c) The EDAA mutant seemed to show an intermediate phenotype between 
GRHL2 WT and GRHL2 (-) [4.] Analysis of genes with overlapping GRHL2/KMT2C binding sites 
(according to UCSC Genome Browser) by CHIP-qPCR using a CHIP validated KMT2C antibody 
revealed that EDAA GRHL2 cells were not able to recruit KMT2C to these select promoters 
without a GRHL2 interaction in Mcf10aneoT+TGF-β cells. This shows that GRHL2 is essential for 
KMT2C recruitment at particular genes that have binding sites for both GRHL2 and KMT2C 
(TP63, CLDN4, RAB25, CDH1, OVOL2). (Fig 7, d) [5.] Functional assays to determine 
characteristics of the EDAA and Δ425-437 GRHL2 mutants revealed that both mutants were 
resistant to anoikis (Mcf10aneoT+TGF-b) and NK attack (Mcf10aneoT+TGF-b, HMLE-MSP) in a 
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manner similar to empty vector control cells, in contrast to strong sensitization observed with 
GRHL2 WT overexpression. (Fig. 7 e,f). 
We also explored the effects of KMT2C/D knockout using an Mcf10a series that had 
KMT2C/D homozygous or heterozygous knockouts, previously generated by others in the lab. 
Messenger RNA expression levels of classical epithelial and mesenchymal genes were mostly 
unchanged by homozygous knockout of KMT2C, however, when this was combined with a 
heterozygous knockout of KMT2D, we noticed an inversion of gene expression signature, with 
epithelial genes no longer expressed (CDH1, GRHL2, OVOL, ESRP, RAB25 ICAM-1), and 
mesenchymal genes concurrently turned on (ZEB1, Collagen 8a, SRGN, DCN, MMP2) (Fig. 7, 
g,h). KMT2C-/-/KMT2D+/- cells also exhibited a profoundly altered morphology, with an 
elongated, spindly appearance, further evoking an EMT phenotype (Fig. 7, i). This suggests that 
the histone methyltransferases KMT2C and KMT2D are utilized by lineage defining machinery, 
perhaps most notably GRHL2, whose downregulation upon KMT2C/D knockout suggests a self- 
 
reinforcing positive feedback loop. We were curious to see if this EMT induced by KMT2C-/- 
 
/KMT2D+/- would also confer resistance to NK attack. Curiously, we found that the KMT2C-/- 
 
/KMT2D+/+ cells were sensitized, while the KMT2C-/-/KMT2D+/- cells were comparatively much 
more resistant, but at a level similar to control (Fig. 7, j). This experiment warrants further 
investigation. 
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Figure 7. KMT2C/D interaction is important for GRHL2-mediated NK sensitization. A.) 
Morphological brightfield images of Mcf10aneoT+TGF-β (+GRHL2 WT/ EDAA / Δ425) with 
ectopically expressed GRHL2 mutants plated at subconfluent densities. B.) qPCR measure of 
mRNA transcripts of various GRHL2-induced genes in cells containing GRHL2 WT versus 
mutants. C.) Anoikis assay conducted on Mcf10aneoT+TGF-β stably expressing GRHL2 WT or 
mutants were suspended in Mcf10a medium + 10% methylcellulose, then assayed using Caspase 
3/7 glo signal at timepoints. D.) CHIP-qPCR measure of KMT2C occupancy of select promoters 
containing binding sites for both GRHL2 and KMT2C in cells with WT, unexpressed, or EDAA 
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mutants indicates loss of KMT2C recruitment in the absence of GRHL2 or GRHL2 interaction. D.) 
Anoikis assay on Mcf10aneoT+TGF-β+vec (“NTM”) with GRHL2 WT or mutants ectopically 
expressed. Assay conducted with a minimum of 2 technical duplicates per cell line. E,F.) NK 
assay on Mcf10aneoT+TGF-β or HMLE-MSP with ectopically expressed GRHL2 WT or mutants. 
NK assays were conducted in triplicate, statistical analysis was conducted using a Student’s 
Two-tailed T test. G,H.) qPCR mRNA expression in Mcf10aP KMT2C/D Crispr-Cas9 K.O. cells 
reveals that epithelial/mesenchymal gene expression patterns are de-stabilized when KMT2C 
and KMT2D are altered. I.) Brightfield phase-contrast microscopy at 20X magnification. J.) NK 
assay conducted on KMT2C (MLL3) and KMT2D (MLL4) versus WT Mcf10aP cells. Cells were 
plated at 4.5x104 cell per well in duplicate. NK92mi cells were added at a 3:1 ratio and assayed 
for 7hrs. Student’s Two-tailed T test was used for statistical analysis. 
Taken together, this data reveals that GRHL2’s direct interaction with KMT2C/D is 
required for activation of epithelial gene expression and adoption of functional characteristics 
typical of the epithelial state (epithelial morphology, anoikis sensitivity, NK sensitivity). We 
proposed that GRHL2 is an important mediator of immune sensitivity, and that this vulnerability 
is mediated, at least in part, through maintenance of ICAM-1 expression. qPCR and western blot 
analysis indicated that neither EDAA nor Δ425-437 induced ICAM-1 expression to the levels 
that WT GRHL2 does in Mcf10aneoT+TGF-β cells (Fig. 8, a,b). KMT2C-/-/KMT2D+/- mutant cells, 
in the presence of WT GRHL2, also exhibited reduced ICAM-1 mRNA expression (Fig 7. g). 
Further, UCSC Genome Browser KMT2C and GRHL2 tracks suggested overlapping binding in the 
 
ICAM-1 promoter. Similar to other promoters containing GRHL2/KMT2C overlap, KMT2C 
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occupancy on this promoter was reduced in EDAA GRHL2 mutant cells as assayed by CHIP- 
qPCR using a KMT2C CHIP-validated antibody (Fig 8. d,e). 
To conclude, utilization of a GRHL2 KMT2C/D non-interacting mutant previously 
generated in our lab, emphasizes the importance of KMT2C/D in GRHL2’s regulation of gene 
expression. Not only does GRHL2 depend on KMT2C/D to activate epithelial gene expression, 
but KMT2C is dependent upon GRHL2 in order to be recruited to a subset of genes that contain 
GRHL2 and KMT2C binding sites, as demonstrated by loss of KMT2C binding in CHIP-qPCR 
experiments. These results also determine that NK-sensitizing gene expression in some 
epithelial lineages is under positive regulation from GRHL2/KMT2C/D because GRHL2 EDAA 
mutant, which induced an EMT gene expression program, exhibited altered resistance to NK 
attack. 
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Figure 8. GRHL2 and KMT2C interaction is necessary for ICAM1 mRNA and protein expression. 
A.) qPCR expression of ICAM1 mRNA indicates inability of GRHL2 mutants to activate gene 
expression significantly above control when stably expressed in Mcf10aneoT+TGF-β cells. B.) 
Western blot on Mcf10aneoT+TGF-β cells stimulated with IFN-γ demonstrates reduced capacity 
for ectopic GRHL2 mutants to activate ICAM1 protein expression. C.) Quantification normalized 
to GAPDH signal. D.) UCSC Genome Browser tracks indicate overlap of GRHL2 and KMT2C 
predicted binding sites from curated CHIP-seq data near promoter region of ICAM1. E.) qPCR 
product from CHIP-qPCR in Mcf10aneoT+TGF-β using Chip-validated KMT2C antibody 
demonstrates lack of KMT2C localization to ICAM1 genomic region in cells stably expressing 
GRHL2 non-interacting mutant (EDAA). 
I.g. EMT signature anti-correlates with Interferon signature in Lung Adenocarcinoma patient 
samples (TCGA). 
The preliminary data involving ICAM1 and interferon response prompted us to check The 
Cancer Genome Atlas (TCGA) for correlations between epithelial state and interferon response 
in the context of clinical patient samples. We selected Lung adenocarcinoma patients because it 
is known to be an immune-infiltrated cancer type. Patient samples were stratified into quartiles 
based upon their expression of an 18-gene EMT signature (Gibbons & Creighton, 2018). EMT 
score was then correlated with a panel of 47 Interferon-related genes, after their expression 
was normalized to IFN-γ transcript levels within each patient sample. This normalization should 
correct for differences in immune infiltrate and cytokine stimulation. GRHL2 was used as a 
positive control for a low EMT score. Correlation was calculated as deviation from a random 
distribution (0.5:0.5) after normalization. Intriguingly, our analysis showed that low EMT score 
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(Q1) correlated with high IFN-pathway gene 
expression (Q4) for the majority of the genes analyzed 
(Table 2). Patients with tumors that have a high EMT 
score (Q1) correlated with lower IFN-pathway gene 
expression. Although correlative, this data supports 
the notion that the epithelial state is better suited to 
amplify interferon response. This could be a result of 
tumor microenvironmental modulation, such as 
chemokine production and promotion of immune cell 
recruitment, and/or could reflect tumor cell intrinsic 
maintenance of interferon response upon stimulation 
by immune cell-secreted cytokines. 
 
 
 
Table 2: EMT anti-correlates with IFN-related genes in 
lung cancer. After quartile grouping according to EMT 
score, IFN-γ-normalized expression of IFN-related 
genes was found to anti-correlate with EMT score. 
Random distribution = (0.5:0.5). 
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1.h. GRHL2 protein expression correlates with time to relapse in Breast cancer 
Analysis of patient data across cancer types reveals a context-dependent role for GRHL2 
in predicting clinical outcomes. “KMplot.com” houses a free, online Kaplan-Meyer 
plotting software that can be used to query mRNA expression across multiple databases 
(TCGA, GEO, etc.),correlating expression with clinical characteristics (Nagy, Lanczky, 
Menyhart, & Gyorffy, 2018). We utilized this database to produce KM plots for GRHL2 
using the “pan-Cancer” setting. Lung SCC (HR: 0.7), stomach adenocarcinoma (HR:0.6) 
and bladder carcinoma (HR: 0.7) exhibit statistically significant better overall survival in 
patients with GRHL2 mRNA above median. Conversely, Kidney (HR:1.9), Breast cancer 
(HR:1.7), and Pancreatic ductal adenocarcinoma (HR: 2.4) correlate high GRHL2 mRNA 
with worse overall survival (Fig.9 a,b). The dichotomous role of GRHL2 clearly requires 
in vivo experiments to better understand the context-dependent nature of its function. 
The Frisch lab had previously devised and initiated a transgenic GRHL2 murine 
recurrent mammary tumor model. The model was developed by Josh Farris MD,PhD, 
Philip Pifer MD, PhD and Steven Frisch PhD. Later stages of the project were maintained 
by Hannah Wilson PhD and the author. Final data analysis was conducted by Steven 
Frisch PhD and the author (unpublished data: Pifer P., Farris J., Wilson H., Frisch S.M.). 
Mice expressing a mammary gland-specific MMTV-GRHL2 transgene were crossed with 
tetO-neuNT;MMTV-tTA (MTB/TAN) mice. Upon administration of doxycycline, mice 
develop neu oncogene-driven mammary tumors. GRHL2(+) and control mice exhibit 
analogous tumor formation. Removal of doxycycline causes efficient regression of 
primary tumors in this model. Mammary glands with MMTV driven GRHL2 expression 
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showed almost a complete lack of recurrent tumors (0-7%), compared with control mice 
(29.4%). Unfortunately, this experiment did not reach statistical significance which likely 
stemmed from two problems; 1.) The p-value if comparing MMTV-GRHL2 (0/13) versus 
control (5/17) recurrence was 0.052. A larger number of mice would be advisable for 
repeating this experiment. 2.) One of the mice in the MMTV-GRHL2 tumor did have a 
recurrence, although the recurrence, unexpectedly, did not express GRHL2, although it 
was anatomically located in the mammary gland. Including this mouse in the recurrence 
data would mean that 1/13 (7%) of MMTV-GRHL2 mice had recurrence compared to 
5/17 (29.4%) in control (Fig 9.d). This is not a statistically significant result. Because the 
experiment did not reach significance in a reliable way, we cannot publish the results 
and the data must be interpreted with caution, however the results show a trend 
towards GRHL2 suppressing recurrence and warrants further investigation of this 
phenomenon. Future studies should use a higher (n) of mice because although the 
number of mice developing a primary tumor was high, the recurrence rates in both 
groups was low, making statistical analysis challenging within the sample sizes. 
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Figure 9. GRHL2 mRNA correlations in patient databases. Using the “pan-cancer” 
RNAseq option, we plotted Overall Survival against GRHL2 mRNA expression for various 
cancer types. A.) GRHL2 mRNA correlates with better OS in Lung Squamous Cell 
Carcinoma (HR=0.7 p=0.012), Stomach adenocarcinoma (HR=0.6, p=0.0037), and 
bladder carcinoma (HR=0.67, p=0.0067). B.) GRHL2 mRNA correlates with worse OS in 
Kidney renal clear cell carcinoma (HR=1.9, p=0.0004), Kidney renal papillary cell 
carcinoma (HR=1.89, p=0.035), and Pancreatic ductal adenocarcinoma (HR=2.4, 
p=0.0026). C.). A mouse MMTV-GRHL2 recurrent tumor model produced a trend towards 
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lower rates of recurrence in mice expressing mammary-gland specific GRHL2, although 
the results did not reach statistical significance ( GRHL2- 7% recurrence rate / control- 
24.9% recurrence rate). The mouse tumor model was initiated by Philip Pifer MD,PhD, 
Josh Farris MD, PhD, and Steven Frisch PhD, latter stages of the project were maintained 
by Hannah Wilson, PhD. 
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Chapter I: Conclusion 
 
 
 
Diagram 3: The significance of GRHL2 in tumor biology. Novel proposed roles of GRHL2 
boxed in purple. 
Our data supports the hypothesis that GRHL2’s epithelial programming includes 
maintenance of pathways promoting sensitivity to NK-mediated cell death. The epithelial, 
rather than mesenchymal state, in Mcf10aneoT, HMLE, HT1080, and BT549 cells exhibited 
enhanced sensitivity to cell-mediated cytotoxicity by human Natural Killer cells. Numerous 
avenues potentially directing sensitivity were explored, but ICAM-1 expression appeared to be 
the most consequential in cells where the epithelial state was maintained by GRHL2 expression. 
ICAM-1 expression was epigenetically regulated by GRHL2’s recruitment of KMT2C to the 
promoter of this gene, likely orchestrating permissive chromatin architecture for transcription. 
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We showed that GRHL2 repressed autophagy in HT1080 fibrosarcoma cells, and repressed the 
chondroitin sulfate proteoglycan Serglycin in HT1080 and Mcf10aneoT+TGF-β cells; though not 
significantly altering NK sensitivity in our model, these attributes may be consequential for 
other realms of tumor biology. We explored the role of epithelial versus mesenchymal matrix 
composition and stiffness, and hypothesize that differences may modulate target cell 
tenseness, influencing killing dynamics by NK cells. 
Our data would predict GRHL2 dependent loss of ICAM-1 expression to be an avenue of 
immune evasion during the oncogenic EMT. Evidence from multiple models clearly 
demonstrate that hybrid or partial EMT can contribute to other tumorigenic properties such as 
plasticity, sphere-formation, tumor establishment, drug resistance, etc. (M. K. Jolly et al., 2019; 
Mohit Kumar Jolly et al., 2016; Strauss et al., 2011). It would be interesting to measure the 
levels of GRHL2 expression during these hybrid states, and consequently, ICAM-1 expression. 
Our data agrees with the well-documented central role of ICAM-1 in immune effector cell- 
mediated cytolysis. Future studies should attempt to replicate these findings in other models of 
EMT/MET, especially in the context of circulating or disseminated tumor cells. Therapies aimed 
at preserving ICAM-1 expression could prove useful in the context of immunotherapies in order 
to ensure that checkpoint blockaded immune cells are still able to form immune synapses with 
their target cells. As mentioned above, irradiation has been shown to upregulate ICAM-1 
expression, and a study conducted in acute myeloid leukemia (AML) showed reinvigorated NK 
cells caused paracrine activation of ICAM-1 on target cells (Parameswaran et al., 2016) (Jeong 
et al., 2018). This underscores the notion that ICAM-1 is responsive to, and reliant on, various 
stimuli, in addition to IFN-γ. Conversely, EMT has been associated with upregulation of the 
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immune checkpoint molecule PD-L1 in various contexts including p53-mutant pancreatic 
cancer, cisplatin-resistant lung cancer, and gastric carcinoma (Shen et al., 2019; Song et al., 
2020; Xu et al., 2019). Future experiments should query if GRHL2 expression, through ICAM-1 
promotion, can boost response to PD-L1 checkpoint blockade in these contexts. 
We demonstrated that GRHL2 enforces sensitivity to NK attack through its interactions 
with epigenetic modifiers, which it uses to promote expression of an NK-sensitizing pathway. To 
be clear, GRHL2 is not a frequently mutated gene according to patient databases (TCGA), 
however it’s functional partners KMT2C and KMT2D are two of the most highly mutated genes 
across all cancers: KMT2D=3rd and KMT2C=7th according to the National Cancer Institute 
Genomic Data Commons (GDC) (Fagan & Dingwall, 2019). KMT2C and KMT2D are generally 
regarded as tumor suppressors, as illustrated by the following evidence. TCGA analysis of 958 
breast cancer patients found that KMT2C and KMT2D were altered in 6.99% and 2.40% of cases, 
respectively, and that KMT2C copy number amplification (CNA) significantly associates with 
survival, though mRNA expression did not (L. Liu, Kimball, Liu, Holowatyj, & Yang, 2015). In 
hormone receptor positive breast cancer (HRPBC) KMT2C mutation is a negative prognostic 
indicator: death HR:3.25 (p<0.0001). In this setting, it’s inactivation may contribute to hormone 
therapy resistance, as HRPBC cell lines containing a specific KMT2C mutation could become 
estrogen independent in vitro (Manso et al., 2016). Both KMT2C (19.7%) and KMT2D (26.0%) 
are highly mutated in muscle-invasive bladder cancer (MIBC) according to TCGA data, and their 
vulnerability is replicated in an aggressive carcinogen-induced mouse model (BBN), although 
how these mutations contribute to tumorigenesis is still speculative (Fantini et al., 2018). Some 
mutations in KMT2D caused it to be excluded from the nucleus, perhaps precluding it’s 
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epigenetic function (Fantini et al., 2018). On a related note, homozygous mutation of the 
KMT2C SET domain in a mouse model caused early onset of ureter epithelial tumors, which 
were further exacerbated by hemizygous deletion of p53. These urothelial cells also showed 
marks of elevated DNA damage prompting the idea that KMT2C and KMT2D, along with their 
associated epigenetic complex, may serve as important coactivators of p53-mediated DNA 
repair (J. Lee et al., 2009). In cutaneous squamous cell carcinomas (cSCC), a study comparing 
exomes of 12 metastatic tumors determined KMT2D mutation was significantly enriched in 
metastatic tumors compared with primary tumors, with mutation rates of 62% compared to 
31%, respectively (Yilmaz et al., 2017). Whole-exome sequencing also revealed KMT2C to be 
highly altered in osteosarcoma, where it appears to play a role in migration and invasion 
(Chiappetta et al., 2017). Examples can also be found in non-solid tumors, with Follicular 
lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) showing somatic alteration 
frequencies in KMT2D of 32% and 89%, respectively, underscoring the widespread conserved 
role of these lysine methyltransferases as apparent tumor suppressors (Morin et al., 2011). In 
lung cancer, KMT2D positively regulates the super-enhancer of the circadian rhythm regulator 
per2. Loss of KMT2D in this context causes a reliance on glycolytic metabolism (Alam et al., 
2020). This data comports well with previous data from our lab indicating that GRHL2 (likely 
collaborating with KMT2D ) represses the oncogenic glycolytic switch (Farris et al., 2016). 
Our data provides another line of evidence for understanding the implications of 
KMT2C/D function in epithelial cells during tumorigenesis. Our data suggests that loss of 
function of KMT2C/D could, in effect, mimic GRHL2 loss of function to a degree, because 
GRHL2’s inability to interact with these modifiers renders it largely non-functional as far as 
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epithelial gene expression is concerned. Is GRHL2 rendered dysfunctional, permitting EMT, in 
carcinomas that exhibit loss of function in KMT2C or KMT2D? Loss of KMT2C and KMT2D surely 
has other major implications depending on the cell type, and independent of GRHL2 
interaction, but it is worth noting that epithelial gene expression may also be dysregulated. 
The process of EMT is challenging to detect in whole tumor sequencing; the minority of 
cells that downregulate or lose GRHL2, concurrent with EMT, though perhaps contributing 
disproportionately to immune evasion and metastasis, would likely be missed by a bulk 
approach to sequencing tumors. Further, data presented in Chapter II suggests that other 
consequential mechanisms of GRHL2 downregulation may be at play in the tumor 
microenvironment. In Chapter II, we investigate the importance of epithelial phenotype, as 
controlled by GRHL2, in reception and transmission of the interferon response: a critical node in 
innate and adaptive immunity. 
 
 
 
 
Chapter II. GRHL2 Promotes Interferon Signaling in Epithelial Cells. 
 
Chapter II: Introduction 
 
Following on data presented in Chapter I describing the ability of GRHL2 to promote 
expression of the interferon stimulated gene (ISG) ICAM-1, we sought to uncover the breadth  
of GRHL2’s regulation of interferon stimulated genes. We explore epithelial response to double- 
strand RNA (dsRNA), and interferon gamma (IFN-γ): probing the importance of GRHL2 in 
relaying these signals, as well as the effect of their signaling on GRHL2 expression, itself. IFN-γ 
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has previously been shown to induce EMT in cells, however, GRHL2’s involvement in this 
mechanism was not directly implicated (D. Imai et al., 2019; M. Lee et al., 2019; Lv et al., 2015). 
The interferon pathway is a conserved signaling pathway utilized by most lineages of 
human cells. Interferon signaling can be generally broken down into three categories based 
upon distinct receptors: Type I, II & III. These responses are ignited through activation of 
pattern recognition receptors (PRRs) and include many pathogen associated molecular patterns 
such as double stranded RNA (dsRNA) which signals via toll-like receptor 3 (TLR3) or RIG- 
I/MDA5, as well as many other ligands including single strand RNA (ssRNA), CpG DNA, and 
bacterial components (Abe, Marutani, & Shoji, 2019; Schneider, Chevillotte, & Rice, 2014). 
Although arising from distinct ligands, Type I and Type II signaling exhibits downstream cross- 
talk through signal transduction intermediates: some ligand-specific, others shared and 
overlapping. 
The Type II interferon pathway (IFN-II) is predominantly mediated through IFN-γ. IFN-γ is 
mainly derived from CD4+ T cells, CD8+ T cells, and NK cells in the tumor microenvironment, 
and is not thought to be produced by non-immune lineage cell types. It signals through 
homotypic interaction between ligand-bound IFNGR on the membrane, which initiates 
intracellular JAK1,2/STAT1 signaling. Phosphorylated STAT1 goes to the nucleus and recognizes 
“Gamma Activation Site (GAS)” motifs in interferon stimulated genes (ISGs), inducing their 
activation (Schneider et al., 2014). 
As a core component of innate immunity, Type I interferon (IFN-I) constitutes an 
intrinsic first line of defense against viral infection in cells. Generally, and of initial interest to 
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our research, dsRNA gets internalized into cells and may activate endosomal TLR3 or cytosolic 
MDA5/RIG-I (Sabelo Lukhele, Giselle M. Boukhaled, & David G. Brooks, 2019). Activation of 
stimulator of IFN genes (STING) and mitochondrial antiviral-signaling protein (MAVS) promotes 
phosphorylation and subsequent nuclear localization of IRF3 and IRF7. Nuclear import of these 
IRF proteins allow them to localize to “Interferon Stimulated Response Element” (ISRE) motifs 
in regulatory regions of their target genes. This allows for quick transcription of a limited 
number of ISGs, including the very consequential Type I IFNs ( IFNβ) (Schneider et al., 2014). 
Production of these factors provides a positive feedback autocrine signal to reinforce the 
antiviral state of the cell; slowing protein synthesis, upregulating major histocompatibility 
complex (MHC), and degrading viral RNA, while also signaling in a paracrine fashion, spreading 
an antiviral posture to its neighboring cells. Production of Type I IFN provides a ligand for the 
cell surface receptors IFNAR1 and IFNAR2, which activate associated JAK/STAT kinases, 
subsequently forming complexes of phospho-STAT1&2 and IRF9 termed “ISGF3”. This complex 
goes to the nucleus and further activates a wave of ISGs (Sabelo Lukhele et al., 2019; Snell, 
McGaha, & Brooks, 2017). 
In addition to engendering antiviral responses, Type I IFN production also has a well- 
documented tumoricidal role. Its signaling can implement growth arrest and senescence, but 
also caspase activation and apoptosis (Apelbaum, Yarden, Warszawski, Harari, & Schreiber, 
2012; Besch et al., 2009). In the tumor setting, Type I IFN is likely predominantly triggered by 
DNA sensing PRRs activated by surrounding cell death. Treatment of human mesenchymal stem 
cells with IFN-α initiated a senescent phenotype in a dose dependent manner, in the absence of 
significant apoptosis. This IFN-α induced senescence was reliant upon nuclear accumulation of 
58  
promyelocytic (PML) protein aggregates in the nucleus, which were subsequently shown to co- 
localized with p53 (Fu et al., 2015). Intriguingly, it has been shown that spontaneously 
immortalizing Li Fraumani fibroblasts downregulate IRF5 and IRF7 (IRF7 through CpG 
methylation), but that senescing fibroblasts reactivate these factors; IRF5 and IRF7 transfection 
was sufficient to slow growth and induce a senescence phenotype in immortalized fibroblasts 
coincident with activation of other ISGs (Q. Li et al., 2008). In support of this association, drug- 
induced senescence upon administration of the genotoxic compounds 5-bromo-2’-deoxyuridin 
(BrdU) or distamycin A (DMA) in HeLa cells caused induction of IFN-β and, by day six, >5-fold 
induction of 22 ISGs (Novakova et al., 2010). A multitude of Type I IFN response pathways 
relevant to tumor biology exist, including inflammation, generation of an antiviral state, 
apoptosis, pyroptosis, growth arrest and senescence. 
Type I IFN is also critical for various stages of the adaptive immune response. CD4(+) 
Treg cells show numerical reduction in colorectal and melanoma models in response to IFNα 
treatment, however Type I IFN signaling has also been shown to increase immunosuppressive 
IDO and PD-1 expression on Tregs (Snell et al., 2017; Yu, Huang, Zong, He, & Mo, 2016). 
Maintaining CD8(+) T cell fitness in both viral infections and tumor scenarios is critical; Type I 
IFN indirectly enhances their function by promoting dendritic cell (DC) cross-presentation and 
directly promotes their survival and cytotoxicity (Diamond et al., 2011). The tumor 
microenvironment actively modulates interferon receptor on CD8 T cells, downregulating its 
expression to quell robust antitumor immunity. Colorectal cancer mouse models in which 
IFNAR1-stabilized T-cells were adoptively transferred showed significantly improved anti-tumor 
effects compared with wildtype T-cell transfer (Katlinski et al., 2017). IFN-I signaling can also 
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skew the population of CD8+ T cells towards a more cytotoxic phenotype, but with decreased 
renewal capacity. IFNR blockade reversed this trend and allows for emergence of a memory, 
TCF-1(+)CXCR5+ phenotype that is thought to be critical for effective, sustained response to a 
chronic viral infection (Snell et al., 2017) (Wiesel et al., 2012). 
Notable cases from other kingdoms of life suggest the untapped potential of innate 
immunity pathways in controlling viral infection or tumorigenesis. The Pacific Oyster, 
Crassostrea gigas, can be induced to enter a prolonged “innate immune primed” state by 
transient treatment with the double-strand RNA mimetic poly(I:C). This artificial viral mimic 
induced an antiviral state that lasted up to 4 months post-priming, and was partly characterized 
by gene expression representing gene ontology (GO) categories such as “regulation of cell 
death”, “regulation of type I interferon production” and “immune response”. Poly(I:C) 
regulated genes sustained their differential expression patterns from day 1 - day 126 
postpriming, though some regression to control was observed. Primed oyster populations 
maintained 100% survival 10 days post-infection with OsHV-1, while sterile filtered seawater 
control oyster populations had 5% survival at 10 days. The survival advantage of primed oysters 
coincided with a 200x lower viral DNA load, indicating ineffective viral replication after innate 
immune priming compared with the non-primed control (Lafont et al., 2020). 
In a marine vertebrate model, Zebrafish danio rerio were depleted of adaptive immunity by 
homozygous deletion of rag, then compared to rag+/+ zebrafish response upon challenge with a 
lethal dose of spring viremia carp virus (SVCV). Rag-/- fish exhibited an “antiviral alert state”, 
with 40-45% survival compared to 0% rag+/+ survival 12 days post-infection. Rag-/- fish 
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exhibited a 100x lower viral load compared to rag+/+. RNAseq analysis showed an increase in 
genesets corresponding to interferon, apoptotic, and multigene signatures comparing 
uninfected rag-/- versus uninfected rag+/+. Rag-/- fish also exhibited increased active Caspase-3 
IHC staining in tissue. This suggests that some species may activate an antiviral primed state 
that can be maintained long-term and represents a robust response to infection in the absence 
of the adaptive arm of the immune system. Intriguingly, these fish are maintained in nonsterile 
conditions, possibly exposed to a microbiome capable of stimulating this low-level innate 
immunity (García-Valtanen et al., 2017) . 
The Blind Mole Rat (genus Spalax) is a subterranean, long-lived rodent perhaps best known 
for its negligible rates of cancer occurrence despite a relatively long lifespan compared to other 
rodent species. Cancer mortality can account for up to 90% of some rat and mouse species, 
however, tumor development has never been documented in captive Blind Mole Rats. In vitro 
studies using fibroblast cell lines from Spalax judaei and Spalax golani demonstrated a novel 
tumoricidal pathway reliant on Type I interferon secretion. Fibroblast cell cultures underwent 7- 
20 population doubling, ceased to grow, then initiated massive necrotic cell death, resulting in 
“concerted cell death” of the entire population. The factor responsible for this cell death was 
demonstrated to be IFN-β on the basis of GFP(+) viral infectivity assay in HT1080 cells, as well as 
a HEK-blue cell β-galactosidase promoter assay containing an IFN-β responsive promoter that 
was sensitive to conditioned media from different population growth stages of Blind Mole Rat 
cells. The necrotic cell death response was dependent upon p53 and Rb pathways, as 
introduction of SV40 large T antigen abrogated cell death and IFN-β. This remarkable example 
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of a species-specific innate immune response underscores the adaptability and tumoricidal 
potential of the innate arm of the immune system (Gorbunova V, Hine C, & X, 2012). 
These examples from across the Animal Kingdoms showcase the importance and 
effectiveness of first-line innate immunity. Functional and responsive interferon pathways, 
particularly the production of Type I IFNs, are equally critical in Homo sapiens; though perhaps 
not possessing identical mechanisms as Danio rerio or Spalax judaei, dissecting factors that 
regulate the timing, sensitivity and magnitude of this response in Homo sapiens is a priority. 
In light of these observations, the epithelial production of Type I IFN emerges as a 
critical node in both innate and adaptive arms of anti-tumor and anti-viral immunity. As 
reviewed above, modulation of IFN production, receptor expression and signaling have 
implications for tumor progression and resolution. Identifying factors that maintain, or are 
necessary for, the IFN response could inform future understanding of the regulation of this 
process and identify predictors of response to immunotherapies. It is important to note that 
IFN signaling is often two-sided, capable of initiating robust immunity, but also 
immunosuppression in chronic settings. For example, expression of checkpoint molecules is a 
normal physiological response to avoid autoimmunity, but in the tumor microenvironment 
setting these molecules are associated with poor outcomes, while also predicting response to 
checkpoint blockade therapies (D. S. Chen & Mellman, 2017). 
The ramifications of epithelial versus mesenchymal state, or EMT, upon normal 
epithelial IFN I response is not well documented. During embryogenesis, the human embryonic 
stem cell (hESC) constitutively expresses a subset of interferon response genes in the absence 
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of stimulation. These “Intrinsic Interferon Genes” are thought to protect the developing 
embryo from viral pathogens during formative development. Upon differentiation, the genes 
lose their constitutive expression, and the ubiquitous, stimulation-dependent interferon 
response pathway becomes accessible (X. Wu et al., 2018). This intrinsic ISG phenomenon and 
GRHL2’s premier role in establishing epithelial enhancers upon hESC differentiation (A. F. Chen 
et al., 2018) converge upon a possible role for GRHL2 in regulating interferon response 
programs in differentiated epithelial lineages. In airway epithelial cells a TGF-β-induced EMT 
phenotype downregulated IFN I and IFN III expression. Zeb1 mediated repression of IRF1 and 
restrictive epigenetic remodeling, in this context, led to silencing of IFN III contributing, 
pathologically, to defective mucosal antiviral immunity (J. Yang, Tian, Sun, Garofalo, & Brasier, 
2017). In triple negative breast cancer (TNBC), an IFN-β metagene signature predicts better 
prognosis and immune response. Treatment of drug resistant tumor cancer stem cell (CSC) 
populations, shown to lack IFN/STAT signature, with IFN-β was able to revert CSC traits and 
induce epithelial traits (Doherty et al., 2017). 
Speculatively, the extent to which EMT or hybrid EMT/MET could modulate the 
interferon response might have important implications for survival of these cells at primary 
tumor sites, as well as during metastatic dissemination, possibly constituting a survival 
advantage for the individual cell, and altering the immune microenvironment at the population 
level. In breast cancer, high expression of an interferon metagene predicts metastasis in 
ESR1+/ERBB2- tumors, however in ERBB2+ subtype it correlates with low metastasis (Callari et 
al., 2014). This suggests that extrinsic or intrinsic factors influencing interferon signaling could 
have a significant role in tumor biology and progression. 
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We hypothesized that GRHL2 would preserve appropriate IFN response. Stated 
differently, loss of GRHL2 would reduce sensitivity to IFN-γ and dsRNA and deregulate the 
cellular interferon response. We conducted whole transcriptome RNAseq on Mcf10a cells 
treated with these ligands in the presence or absence of GRHL2. The results suggest that GRHL2 
regulates a multitude of ISGs, and, particularly, is required for Type I (IFNβ) and Type III 
(IFNL1,2,3) production. These results provide exciting insights regarding the significance of the 
epithelial versus mesenchymal state for Type I IFN regulation, with implications for antiviral and 
antitumor immunity. 
 
 
 
Chapter II: Results 
 
II.a. GRHL2 regulates subset of interferon response genes (ISGs). 
 
We probed a number of interferon stimulated genes basally and after IFN-γ stimulation 
 
in Mcf10aneoT+TGF-b  (+GRHL2) and HT1080  (+GRHL2). The 
 
results indicate that GRHL2 promotes expression of many 
interferon stimulated genes, but may also repress subsets 
(Fig.10,a) (Table 2). Interestingly, GRHL2-expressing cells 
repressed expression of the top “intrinsic interferon genes” 
conserved across multiple hiPSC and hESC cell lines (Rice, et 
al. 2017) , suggesting that GRHL2 may play a role in 
repressing this subset during transition from pluri- and multi- 
potent stem cells into differentiated epithelial lineages (Fig. 
10,b). This seems paradoxical because expression analysis of 
Table 2 
Effect of GRHL2 
on ISGs 
Induced Repressed 
IFNLR ISG15 
IFIH1 OASL 
DDX58 OAS1 
PDL1 BST2 
ICAM1 EIFL3 
CD155 IFITM1 
CXCL10 IFITM3 
CXCL16 
RNL 
p21 
SOCS 
MLT1b 
TRIMM22 
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GRHL2 shows high expression in hESCs (with high intrinsic ISG activity), so our prediction 
of GRHL2 promoting intrinsic ISG expression was not supported. 
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Figure 10. mRNA transcript levels of select ISGs in Mcf10aneoT and HT1080. A.) GRHL2 
expression favors ISG induction at basal and/or after IFN-γ stimulation in Mcf10aneoT+TGF-β 
cells expressing ectopic GRHL2. Similar results were obtained for favorable ISG mRNA levels in 
qPCRs conducted in HT1080 fibrosarcoma cells ectopically expressing GRHL2. C.) A panel of 
“intrinsic” embryonal ISGs are repressed by GRHL2 expression in Mcf10aneoT cells ectopically 
expressing GRHL2 compared with CRISPR-Cas9 GRHL2 knockout cells. All qPCR results represent 
at least biological duplicates and are normalized to GAPDH or CBX housekeeping gene controls. 
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II.b. GRHL2 is required for Type I and III IFN production in Mcf10aneoT cells. 
 
Based upon differential targeted qPCR expression of various ISGs in the presence or 
absence of GRHL2, we wanted to know if GRHL2’s potentiation and promotion of interferon 
response was pervasive across large swaths of interferon stimulated genes. It is estimated that 
around 5% of the human coding genome is responsive to interferon stimulation (Schneider et 
al., 2014), making whole transcriptome RNAseq analysis a more comprehensive method for this 
investigation. In order to explore IFN-I and IFN-II pathways, we separately treated cells with 
either dsRNA mimetic poly(I:C) or recombinant IFN-γ and compared with untreated control 
cells. Mcf10aneoT (GRHL2 WT), Mcf10aneoT+GRHL2 (O/E) , and Mcf10aneoT+gr sg2 (GRHL2 
CRISPRcas9 K.O.) were treated with either [600U/mL] IFN-γ for 12hrs, or [50ug/mL] poly(I:C) for 
3hrs, in triplicate. To explore differences in ISG expression, we first calculated the fold induction 
of the top 100 most highly upregulated genes in our GRHL2 WT cells after poly(I:C) treatment. 
We compared the induction of these genes with the corresponding induction in GRHL2 K.O. 
cells. Analysis revealed that many of the genes upregulated in WT cells were classical ISGs, and 
that these genes exhibited weaker induction, or no expression, in our GRHL2 K.O. cells (Fig. 
11,a). Strikingly, interferon beta (IFNB1) and interferon lambda 1, 2, and 3 (IFNL1, IFNL2, IFNL3), 
definitive members of Type I and Type III Interferons, respectively, were either marginally, or 
not expressed in the GRHL2 knockout cells after poly(I:C) stimulation (Fig. 11,c). 
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Figure 11. GRHL2 broadly promotes poly(I:C) induced antiviral interferon gene 
expression. Cells were treated in triplicate with 50ug/mL poly(I:C) in Mcf10a media for 3hrs, 
before RNA prep.  A.) RNAseq datasets comparing Mcf10aneoT (GRHL2 O/E, WT, K.O.) were 
used to calculate the most strongly induced genes (ranked by fold change between (-)poly(I:C) 
and (+)poly(I:C)) in GRHL2 WT (middle column). B.) Corresponding fold change is compared in 
GRHL2 O/E (left column) and K.O. (right column). Fold induction calculations used the average of 
triplicates per treatment group. C.) Representative classic interferon response genes (Type I and 
III IFN, IFITs, JAK/STAT, CXCLs) FPKM expression values in triplicate, after poly(I:C) treatment 
comparing Mcf10aneoT WT (left) and K.O (right). 
Conversely, we took the top 99 genes most strongly induced in the K.O. cells after 
poly(I:C) and compared their induction to the same genes in WT (Fig. 11,b). This revealed a set 
of genes that were induced by poly(I:C) more strongly in the absence of GRHL2 (an EMT 
phenotype) and may constitute an interferon response signature that GRHL2 represses. 
To find unifying pathways or processes from the most highly expressed genes, we took 
the absolute expression (FPKM) after poly(I:C) treatment of all genes in the RNAseq comparing 
WT and K.O.. (sample exhibited in Fig. 11,c) We used the final expression level after treatment 
to attempt selection for more biologically relevant ISGs based on higher expression, while 
avoiding artifacts arising from selection of genes with large induction fold changes, but 
extremely low expression values before and after treatment. We submitted these lists to Gene 
Set Enrichment Analysis (GSEA, Broad Institute), querying the gene list against a group of Gene 
Sets from Molecular Signature Database (www.gsea-msigdb.org) that were affiliated with the 
term “interferon”. We found that our GRHL2 WT+poly(I:C) samples were disproportionately 
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enriched for genes contributing to many dsRNA and interferon response gene sets with false 
discovery rates (FDR) <0.25 (Fig. 12, a,c). Conversely, the GRHL2 K.O.+poly(I:C) samples were 
nearly devoid of enrichment in these gene sets (Fig. 12, b). To investigate the genes from our 
GRHL2 WT+poly(I:C) dataset that were most influential on its association with interferon GSEA 
signatures, we conducted Leading Edge Analysis on enriched genesets from our original GSEA 
with an FDR<0.25 and a NES>1.20. This analysis quantifies the number of times that a gene 
appears across multiple gene sets. The top hits and number of appearances in the GRHL2 
WT+poly(I:C) were IRF7, ISG15, TAP1 and IRF1 (Fig. 12, d). Our data suggests that GRHL2 
promotes IFN-I signaling in epithelial cells. Loss of GRHL2 abated IFN-I and IFN-III production, 
indicating a breakdown in the signal transduction process somewhere between ligand 
reception and transcriptional activation of IFN-I and IFN-III. Apart from these specific cytokines, 
GRHL2 also was required for upregulation of numerous other ISGs, which together, contribute 
to enrichment of various GSEA pathways such as “Response to oncocytic virus”, “IFN alpha 
response up”, and “Graft versus host disease 35D up”. 
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Figure 12. Gene Set Enrichment Analysis (GSEA) using Broad Institute Molecular Signature 
Database indicates enriched antiviral and IFN pathways in GRHL2 WT poly(I:C) treated cells. A.) 
RNAseq datasets for poly(I:C) treated Mcf10aneoT GRHL2 WT and GRHL2 K.O. were fed through 
GSEA software to compare enrichment for genes represented in multiple  “Interferon” 
associated Gene Sets from Msigdatabase.org. A.) A list of the top “interferon” gene sets 
enriched in GRHL2 WT cells after poly(I:C) treatment. B.) A list of the top “interferon” gene sets 
enriched in GRHL2 K.O. cells after poly(I:C) treatment. C.) Representative GSEA enrichment plots. 
D.) Leading Edge Analysis conducted through the GSEA software package determined genes 
that most contributed to enrichment of GRHL2 WT in the gene sets from A). 
II.c. GRHL2 sensitizes cells to poly(I:C) and is downregulated by IFN-γ. 
 
Treatment of Mcf10aneoT (GRHL2 WT) cells with IFN-γ downregulated GRHL2 at 48hrs 
(Fig. 13, a) . We chronically treated Mcf10aneoT cells with IFN-γ and observed a transition to a 
mesenchymal morphology. This led us to hypothesize that IFN-γ could downregulate GRHL2, 
thus leading to an epithelial-mesenchymal transition. Western blot analysis of chronic IFN-γ 
treated Mcf10aneoT cells revealed protein expressions consistent with an EMT (loss of GRHL2, 
E-cadherin/gain of N-cadherin, vimentin, and fibronectin.) Interestingly, withdrawal of IFN-γ 
could not rescue this EMT, suggesting that IFN-γ had initiated stable repression of GRHL2 (Fig. 
13, b). In our first experiment we chronically treated the cells with IFN-γ and made lysates when 
changes were observed. To repeat this phenomenon, we treated Mcf10aneoT cells with 
400U/mL IFN-γ and observed convincing EMT morphology in ~7 days. We also conducted an NK 
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assay on Mcf10aneoT versus Mcf10aneoT+ IFN-γ and found that the latter had become 
significantly resistant to cell-mediated NK cytotoxicity. The assay was conducted in the absence 
of exogenous IFN-γ treatment (Fig. 13, c). 
Type I IFN may activate cell death pathways, inducing apoptosis, in some conditions 
(Apelbaum et al., 2012; Bernardo, Cosgaya, Aranda, & Jiménez-Lara, 2013; Chawla-Sarkar M., 
2001). On top of the widespread IFN gene expression augmentation regulated by GRHL2, we 
tested overall viability after transfection with 2ng/mL poly(I:C). Interestingly, we found that 
GRHL2 WT and GRHL2 K.O. exhibited similar viability, while GRHL2 O/E cells were significantly 
more sensitive (Fig. 13, d). Various mechanisms of cell growth arrest and apoptosis in response 
to Type-I interferon signaling have been published. We could speculate that this sensitivity may 
be mediated through Type-I interferon upregulation of TRAIL (TNFSF10), stimulating death 
receptors on neighboring cells and inducing caspase-8 mediated apoptosis. Our RNAseq data 
hints that cells expressing GRHL2 (WT) start to upregulate TRAIL at 3hrs post poly(I:C) 
treatment, while GRHL2 K.O. cells, in contrast, completely turn off expression after poly(I:C) 
stimulation (Fig 13, e). This hypothesis warrants further investigation. 
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Figure 13. IFN-γ downregulates GRHL2, thereby inducing epithelial to mesenchymal 
transition. A.) Normalized GRHL2 mRNA transcript levels decline within 48hrs of ~400U/mL IFN-γ 
treatment. B.) Mcf10aneoT epithelial cells treated with chronic IFN-γ [400U/mL] undergo 
morphological changes consistent with EMT; western blot of cell lysates indicate loss of GRHL2 
protein expression with accompanying E-cadherin loss and gain of N-cadherin and Fibronectin 
expression. Lane 4 represents lysate from EMT’d cells that had IFN-γ removed, suggesting a 
stable EMT was induced, even after withdrawal of the EMT stimulus. C.) Chronic IFN-γ treated 
EMT cells were subjected to an NK assay (in the absence of IFN-γ). IFN-γ induced EMT 
corresponded to significant resistance to NK attack compared to IFN-γ naïve cells. Cells plated in 
triplicate. D.) Transfection of Mcf10aneoT (GRHL2 WT, O/E, K.O.) cells with 2ug/mL poly(I:C) 
revealed heightened cell death in GRHL2 O/E cells compared with both WT and K.O. using 
PrestoBlue cell viability assay. Untreated assayed in duplicate, treated assayed in quadruplicate. 
E.) mRNA expression levels (FPKM) of TRAIL (TNFSF10) in triplicate generated from an RNAseq 
on Mcf10aneoT (GRHL2 WT or K.O.) before and after poly(I:C) treatment. 
Chapter II: Conclusion 
 
ICAM-1 is an interferon stimulated gene whose expression was upregulated by GRHL2 
basally, and upon IFN-γ stimulation. This provoked the hypothesis that GRHL2 played a role in 
transducing or promoting IFN signaling and subsequent gene expression. qPCR analysis of 
HT1080 and Mcf10aneoT cell lines supported this hypothesis; although our sample size of ISGs 
was too small to be able to make broad generalization. We did find that GRHL2 suppresses the 
prolific “intrinsic interferon genes” expressed in early pluri- and multi- potent murine stem 
cells, although the application of this is questionable since murine and human embryonic stem 
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cells are not completely equitable systems; the timing of GRHL2 expression varies during 
development between species. For whole transcriptome RNAseq, our approach of stimulating 
interferon pathways via two distinct mechanisms (IFN-γ, poly(I:C)) across GRHL2 WT, O/E, K.O. 
cell lines gave us much broader coverage and sample size to explore not only individual genes, 
but also pathways altered by GRHL2 expression, or absence, and their implications for Type I 
and Type II interferon responses. 
RNAseq analysis of Mcf10aneoT +GRHL2 WT, O/E, K.O. cells revealed that GRHL2 does 
regulate the dsRNA response and IFN-γ response. We focused on the dsRNA response, as 
GRHL2 WT and O/E cells exhibited robust induction of dsRNA response genes, while GRHL2 K.O. 
cells showed deficits, most strikingly characterized by inability to produce Type I and Type III 
interferon. Our RNAseq data also provides numerous hypothesis-generating pieces of data to 
inform future experiments aiming to discover the mechanism by which GRHL2 influences 
interferon signaling (Table 3). Intriguingly, GRHL2 WT cells express about 2-fold higher MDA5 
(IFIH1) mRNA under basal conditions compared to GRHL2 K.O. cells. MDA5 is one of the core 
cytosolic dsRNA sensors, implicated in responding to longer dsRNA molecules upon which it 
multimerizes, forming microfilaments. Upon poly(I:C) stimulation, MDA5 expression 
dramatically increases ~18-fold with an induced expression ~10-fold higher than the induced 
expression level in GRHL2 K.O. cells. This suggests that GRHL2 K.O. cells, at baseline, are less 
prepared to mount an antiviral response, at least through this pathway. Concerning the MDA5 
pathway, our RNAseq also revealed that a key MDA5 negative regulator, RIOK3, is induced 
strongly by poly(I:C) in GRHL2 K.O. cells (~9  ~25 FPKM), while in GRHL2 WT cells it remains 
poly(I:C) non-responsive. RIOK3 functions as a Serine/threonine kinase that phosphorylates 
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MDA5’s c-terminal region. This disrupts the ability of MDA5 to multimerize with dsRNA. 
Functionally, this leads to dramatic reduction in IFN-β production, which is rescued in RIOK3 
K.O. cells (Takashima, Oshiumi, Takaki, Matsumoto, & Seya, 2015). 
 
Introduced earlier, the interferon regulatory factor 3 (IRF3) protein represents a critical 
portal for transmission of dsRNA stimulation to nuclear signaling. IRF3 protein is regulated post- 
translationally through multiple modes (J. Liu, Qian, & Cao, 2016). Our RNAseq data suggests 
that GRHL2 would be a positive regulator of IRF3 stability by promoting expression of various 
IRF3 regulators. ISG15 is a ubiquitin-like molecule that can be attached to and stabilizes IRF3. 
This process, termed “ISGylation”, is also mediated by HERC5, which acts as a ubiquitin ligase 
for ISG15 (Wong, Pung, Sze, & Chin, 2006). ISG15 is roughly 2.5x more highly expressed basally 
in GRHL2 WT cells, and upon poly(I:C) treatment, its expression is also strongly favored in 
GRHL2 WT cells. HERC5, although essentially not expressed in either cell line prior to poly(I:C) 
stimulation, is induced roughly 7x in GRHL2 WT cells, while it is essentially not turned on in 
GRHL2 K.O. cells. Another piece of evidence implicating IRF3 as a prime suspect of GRHL2’s IFN 
promotion is TICAM1. Also known as TRIF, TICAM1 is an adaptor molecule that transmits signal 
from toll-like receptors to other downstream proteins. TICAM1 is specific for TLR3, the dsRNA 
receptor, and is shown to be essential for subsequent production of IFN-β (Oshiumi, 
Matsumoto, Funami, Akazawa, & Seya, 2003). Our RNAseq data shows that TICAM1 is >2x more 
highly expressed in GRHL2 WT cells at basal conditions, and also retains slightly higher 
expression after poly(I:C) stimulation than GRHL2 K.O. cells. Conversely, CFLAR (or FLIP) is a 
negative regulator of type I IFN response. Loss of CFLAR has been associated with increased 
poly(I:C) induced apoptosis and increased NF-kB and IRF3 response genes. Interestingly, basal 
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CFLAR levels were equal between GRHL2 WT and K.O. cells, but showed strong, though 
variable, upregulation only in GRHL2 K.O. cells. CFLAR has pro-survival activities through its 
binding to TRADD and FADD, thereby blocking association with Caspase 8 and dulling the 
apoptotic response (Handa, Tupper, Jordan, & Harlan, 2011). The strong upregulation of CFLAR 
in GRHL2 K.O. cells, accompanied by mild deficiency in poly(I:C) mediated TRAIL (TNFSF10) 
upregulation could provide an explanation for the observed survival advantage of GRHL2 K.O. 
cells during transfection of poly(I:C). 
 
 
Table 3. Interferon related genes regulated by GRHL2. Raw RNAseq expression values in 
triplicate from Mcf10aneoT versus Mcf10aneoT +GRHL2 K.O. treated with 50ug/mL poly(I:C) for 
3hrs. RFTN1: Raftlin 1, RFTN2: Raftlin 2, TICAM1: toll-like receptor adaptor molecule 1, MDA5: 
interferon induced with helicase C domain 1, RIOK3: RIO Kinase 3, CFLAR: CASP8 and FADD like 
apoptosis regulator, ISG15: interferon stimulated gene 15, HERC5: HECT and RLD domain 
containing E3 ubiquitin protein ligase 5, TRAIL: TNF superfamily member 10. 
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Production of Type I interferon is an important mediator of antiviral and antitumor 
immunity. Besides communicating a viral distress response to nearby cells, IFN-β can cause cell- 
cycle arrest, senescence and apoptosis in surrounding tumor cells (Snell et al., 2017). Apoptosis 
is mediated through TRAIL upregulation in melanoma and breast cancer, and Caspase-8 
activation in cervical carcinoma (Apelbaum et al., 2012; Bernardo et al., 2013; Chawla-Sarkar 
M., 2001). But this direct cytostatic and apoptotic effect must also be interpreted in light of the 
diverse impact that IFN-I has on the immune microenvironment: effecting dendritic cells, 
macrophages, B cells, CD4+ and CD8+ T cells (Snell et al., 2017) , as well as the timing and 
duration of its signaling. Although inflammatory in nature, chronic IFN-I signaling can also lead 
to upregulation of PD-L1 and immunosuppression: altering the phenotype and activity of cells 
of the innate and adaptive immune system (Snell et al., 2017). It is important that cells counter- 
regulate IFN-I production; demonstrated by dramatic reduction in IFN-I expression after the 
initial acute phase, though many ISGs are still expressed, or are primed for expression in this 
context (Snell et al., 2017). We currently have no evidence to suggest that GRHL2 WT or O/E 
cells have an inability to turn off, or reduce IFN-I production after the initial acute phase 
following stimulation, though it would be interesting to determine if the kinetics of ISG 
expression were altered in GRHL2 WT versus O/E; are ISGs more rapidly produced initially, and 
IFN-I production slower to diminish after the acute phase in cells constitutively overexpressing 
GRHL2? 
In future studies we would like to address this question within the context of a 
proposed role for GRHL2 in epigenetically priming interferon response genes. Intriguingly, 
GRHL2 binding sites are located in regulatory regions of various ISGs, and overlap with some 
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interferon regulatory factor (IRFs) binding sites. The extent to which GRHL2 preferentially, non- 
randomly locates to interferon related genes, above its distribution across the rest of the 
genome, would give us an indication of its potential as an epigenetic regulator of the interferon 
response, perhaps in a manner similar to its regulation of epithelial/mesenchymal genes (via 
KMT2C/D recruitment, p300 inhibition.) This appeared to be GRHL2’s manner of regulating the 
ISG ICAM-1, as demonstrated by our CHIP-qPCR; KMT2C was not recruited to ICAM-1 promoter 
in the absence of a GRHL2 interaction (GRHL2 EDAA cells) effectively silencing this gene. 
GRHL2 is an epithelial master transcription factor, responsible for overseeing a wide range 
of lineage determining genes, however, inclusion of interferon stimulated genes, particularly in 
the presence of dsRNA or IFN-γ was unforeseen. This raises important implications not only for 
cancer related properties and anti-tumor immunity, but also for viral infection of epithelial 
cells. Future experiments should address the infection and replication competence of virus in 
epithelial cells in the presence (WT) or absence (K.O.) of GRHL2. Our data showed that GRHL2 
recruited KMT2C to the ISG ICAM-1 promoter in a GRHL2-dependent manner. Future 
experiments should explore if this mode of epigenetic regulation is conserved in 
promoter/enhancer regions of various other ISGs. This could be quantified by CHIP-seq of 
epithelial cells expressing endogenous GRHL2 before and after poly(I:C) treatment. Does GRHL2 
bind these genes upon stimulation with poly(I:C)? A complementary approach would involve 
ATAC-seq of accessible chromatin regions before and after poly(I:C) in epithelial cells expressing 
endogenous GRHL2 or GRHL2 K.O. This would indicate the importance of GRHL2 in establishing 
open, transcriptionally permissive sites at ISGs upon stimulation with ligand. As suggested 
above, these experiments could also be conducted with GRHL2 O/E epithelial cells to address 
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whether increasing levels, or enforced overexpression, of GRHL2 causes a sustained or non- 
counter-regulated interferon response, specifically implicating sustained GRHL2-mediated 
epigenetic control. This could have implications for the tumor microenvironment and immune 
cells, as chronic type I IFN production has been shown to be immunosuppressive (S. Lukhele, G. 
M. Boukhaled, & D. G. Brooks, 2019). 
 
To conclude, GRHL2 has emerged as an important regulator of immune sensitivity. The 
presence of GRHL2 protein maintains expression of immune sensitizing genes such as ICAM-1 
through epigenetic interactions. Expanding GRHL2’s well documented role as an epithelial 
master transcription factor, our data also brings a multitude of interferon stimulated genes into 
GRHL2’s wheelhouse of regulated genes. This data further solidifies the notion that appropriate 
immunological relationships are a facet of the epithelial state, as mediated by the master 
transcription factor GRHL2. 
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Diagram 3. The significance of GRHL2 in tumor biology. Novel proposed roles boxed in purple 
 
 
 
 
Materials and Methods 
 
Cell lines 
 
MCF10a-derived, HMLE-derived and HT1080-derived cell lines were obtained and cultured as 
described previously. MCF10aneoT cells were induced to undergo EMT by treatment with 
20ng/ml TGF-β for three days, and then outgrowth in the absence of TGF-β. Mesenchymal cell 
lines (MCF10aneoT+ TGF-β, abbreviated as NTM, the Mesenchymal Subpopulation derived 
from HMLE, abbreviated as MSP, HT1080 fibrosarcoma cells and BT549 triple negative breast 
cancer cells) were reverted to an epithelial phenotype by retroviral expression of GRHL2 in the 
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vector pMXS-IRES-puro, as described previously, or by expression of mir200c (see below). 
 
NK92-MI cells (American Type Culture Collection) were cultured in Alpha Minimum Essential 
medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 
g/L sodium bicarbonate (Life Technologies) containing 0.2 mM myo-inositol, 0.1 mM 2- 
mercaptoethanol, 0.02 mM folic acid, 10% horse serum, 10% fetal bovine serum and 5 ng/ml IL- 
2 (R and D Systems). BT549 cells (grown in RPMI-1640+5% fetal bovine serum+10 µg/ml 
insulin+penicillin-streptomycin-glutamine) with inducible mir200c expression were constructed 
by subcloning the mir200c sequence into pTRIPZ, packaging lentiviruses, infecting BT549 cells 
and selecting for puromycin-resistance. The CRISPR/cas9 lentiviral constructs for knocking out 
human GRHL2 were kindly provided by Dr. B. Hogan, which were packaged in 293T cells and 
infected into target cell lines, as we described previously. GRHL2 knockout (>95%) was verified 
by Western blotting total puromycin-resistant populations; subcloning of knockout cells proved 
unnecessary. The CRISPR/cas9 mediated knockouts of KMT2C and KMT2D were generated by 
subcloning guide sequences (For KMT2C: M3CrE3-F: caccgGCGATCTGTGTCTGAGGAAT 
M3CrE3-R: aaacATTCCTCAGACACAGATCGCc. For KMT2D: M4CrE3-F: 
caccgTCCCGCTGCCCGTGTAGACT 
M4CrE3-R: aaacAGTCTACACGGGCAGCGGGAc) into the BsmBI sites of pLenti-Crispr-v2 or 
pLKO5.sgRNA.EFS.tRFP (Addgene). Lentiviruses were packaged and infected into MCF10a 
(subclone MCF10aP) cells as described, followed by sequential selection for puromycin- 
resistance and flow-sorting for RFP. Indels that caused reading frame shifts were identified by 
generating PCR fragments from genomic DNA, which were subcloned into pTOPOII (Life 
Technologies) and sequenced. MCF7 and MCF7-EMT cell lines were kindly provided by Dr. 
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Bruce White (University of Connecticut). HT1080+E1a cells were described previously. To 
generate target cells expressing nano-luciferase, cell lines were infected with the Nano- 
luciferase expressing lentiviral construct pLenti6.2-Nanoluc-ccdb (Addgene) and selected for 
blasticidin resistance (10 µg/ml). 
 
 
 
Western Blots 
 
Cells were lysed in 1x LDS Sample buffer containing 50mM DTT, then heated at 70C. Lysates were run on 
Novex 4-12% Bis-tris gels at 120V for 2hrs. After transfer, membranes were incubated with indicated 
antibodies, then developed using SuperSignal West Pico Chemiluminescent substrate. 
NK cytotoxicity assays 
 
Assay 1: Target cells were plated in 12-well format at 3.5x104 cells per well in triplicate. At 
least one day later, target cells were stained with 1µM CMFDA for 25 min in serum free 
medium, and washed 3x with complete medium. NK92-MI cells were added to wells in the 
85  
appropriate target cell medium at 3:1 effector to target ratio. At the time points indicated, 
wells were gently washed 3x with complete medium, and cells were lysed in 300uL of 3% SDS 
solution; 100uL of this sample was read in a black opaque 96-well plate (492 excitation/530 
emission) in a BioTek Synergy H1 Hybrid Reader. Signal from (+)NK wells divided by (-) NK wells 
to calculate viability. 
Assay 2: This assay was developed and validated for NK killing previously. Nano-luc expressing 
target cells (see above) were plated at 3.5x104 cells in triplicate in a 12-well plate. The following 
day, NK92-MI cells were added in target cell medium, and, at the indicated time points, 25 µL 
aliquots of the culture supernatant were assayed using the Nano-Luc Assay System (Promega). 
To determine percentage of cells killed by NKs, a non-NK-treated well of target cells was lysed 
in 500 µL of Cell culture lysis buffer (Promega) to measure total nano-luciferase activity. 
FASL cytotoxicity was assayed by plating cells at 4.0x104 per well in triplicate in 12-well plate. 
The next day, Super-FASL (Enzo) was added to 50 ng/mL. At the indicated timepoints, cells were 
washed 2x with 1X PBS and assayed for caspase activation using the Caspase-glo system 
(Promega). 
To assay cells for granzyme B cytotoxicity, target cells plated at 4.0x104 cells per well in 12-well 
plate. The following day , cells were washed in serum-free medium. Cells were permeabilized 
to allow granzyme B entry using streptolysin-O (Sigma) at concentrations that were pre- 
optimized to produce low spontaneous death but promote granzyme B killing (typically, about 
100 ng/ml). Granzyme B, purified as described previously from YT cells, was added to 400 
ng/mL and wells were monitored for cell death. At the indicated time points, 0.1 volumes of 
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Presto Blue Viability Reagent (Life Technologies) was added to wells and incubated 20min at 37° 
 
C. Aliquots (150 µL) were assayed for fluorescence (560nm excitation/ 590nm emission) in 
opaque, black 96-well plates. Presto blue signal from wells treated with streptolysin-O alone 
were used to calculate viability. 
Autophagic Flux Assays 
 
HT1080 +/- GRHL2 cells were retrovirally infected with a tandem GFP/RFP-LC3 vector, then flow sorted 
to select for GFP(+) cells. Following selection, HT1080 +/-GRHL2 tfLC3 cells were plated onto coverslips 
in wells of a 6-well plate at ~50% confluence. 24hrs later cells were Serum Starved in HBSS for 2 hours, 
then either fixed or treated with Bafilomycin (100nM) for 2hrs. Cells were then fixed in 2% 
formaldehyde for10 min then permeabilized in 0.5% TX100 in PBS for 10min. The slides were then 
imaged using a Zeiss Axiovert 200M Fluorescence Microscope. Fields were then quantified for LC3 
punctae using NIS Elements AR software in order to generate the autophagic flux for each cell line. 
Fields quantified: n=4 for all cell lines (except GRHL2+baf. n=5). Cells quantified MXS: n=2507, MXS+baf: 
n=5298, GRHL2: n=2658, GRHL2+Baf: n=8294 
Autophagic Flux= [(Baf. Treated # LC3 punctae) – (Untreated # LC3 punctae)] 
(pcDH1-tflc3.dna was a generous gift from Dr. Wang, Penn State) 
 
 
 
NK Conjugation Assay 
 
Target cells were plated at 3.5x104 cells/well in 12 well plate. 24hrs later, target cells were 
stained with 1 µM CMPTX in Serum Free medium for 25min and NK92-MI cells were stained 
with 1 µM CMFDA in serum Free medium for 25 minutes. Cells were washed 3X, then stained 
NK92-MI cells were resuspended and added to stained target cells in 3:1 effector/target ratio in 
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the presence of 50 µM ZVAD-FMK. At time points, cells were gently washed 3x with complete 
medium to remove unconjugated NK92-MI cells, then fixed in 2% paraformaldehyde for 10 min 
and washed 3xX. The plates were then imaged at 10x and 20x magnification using an 
epifluorescence microscope (Zeiss Axiovert). GFP and Texas Red Channels were used to detect 
CMFDA and CMPTX stain, respectively. Images were then quantified for NK/target ratios using 
Image J software from the WVU Microscope Core Imaging Facility. 
Anoikis Assay 
 
Cells were plated at equal densities into low attachment cell culture plates in Mcf10a media 
 
+0.5% methylcellulose. Cells were incubated at 37C/5% CO2. At time points, cells were re- 
suspended and an aliquot was taken and mixed 1:1 with Caspase 3/7 glo reagent (Promega), 
incubated for 30’, then read on a Wallac Envision Platereader to quantify anoikis. 
qRT-PCR 
 
Duplicate or triplicate total RNAs were prepared from cells in 60mm dishes using the Qiagen 
RNeasy Plus Mini kit. RNA (2.5 µg) were converted to single strand cDNA using the Superscript 
III kit (Life Technologies). One microliter of (3:1 diluted) cDNA was assayed in 20 uL reactions 
using the PowerUp SYBR green master mix (Applied Biosystems) on an Applied Biosystems 7500 
thermocycler. GAPDH was used as the internal control for normalization. 
The following primer sets were used: 
 
 
gene Primer F Primer R 
DCN agaagctctcctacatccgc ccaagtgaagctccctcaga 
SRGN attttcccaccttgacacca ttttatggccatgggaatat 
ZEB1 catacacctactcaactac tttcatcctgatttccatt 
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Col8A1 catttaccgccgagctaacc tgtctgcgggttgtagttct 
Snail gaaaggccttcaactgcaaa tgacatctgagtgggtctgg 
Twist cgggagtccgcagtctta gcttgagggtctgaatcttg 
Rab25- 
2 
cctaaccaagcaccagacct gctgttctgtctctgcttgg 
CDH1- 
2 
tgaagaaggaggcggagaag ctcagactagcagcttcgga 
ESRP1- 
2 
tttgaatccacgagcactgc taagtccatcctcggttgca 
MMP2- 
2 
aggaggagaaggctgtgttc ctccagttaaaggcggcatc 
TP63-2 atgcccagactcaatttagtga ttctgcgcgtggtctgtgt 
OVOL2 tgcaacgtctgcaataaagc acgtgcaggtacaggtcctc 
EPCAM tgcagggtctaaaagctggt ccctatgcatctcacccatc 
ITGB6 tgcgaccatcagtgaagaag gacaaccccgatgagaagaa 
CLDN4 ccggccttatggtgatagtg gcggagtaaggcttgtctgt 
IRF6 gtgaatgccatcttcttccttct cccaggccaaatctccttct 
ICAM1- 
2 
atacaacagcatttggggcc ccacttcccctctcatcagg 
Wnt5a cccgatttagcagtgtcagc tacacagtgccagtctcagg 
RAET1L cttctgttcctgctgttcgg cgggtgtgactgtcttgttg 
S100A4 gagcaacttggacagcaaca tcatttcttcctgggctgct 
CD112- 
2 
ccatgtatgtgtgagctgcc tttctctgggctcatgggtt 
CD155- 
2 
tggggtgaaaatgtctgtgc ggtttactccagcctccact 
GAPDH tgcaccaccaactgcttagc ggcatggactgtggtcatgag 
   
 
 
 
 
 
Antibodies 
 
 
Antibody Application Company Catalogue #/Ref. 
E-Cadherin Western Blot BD Bioscience 610181 
WDR5 Western Blot Cell Signaling D9E1I 
GRHL2 CHIP/Western Blot Sigma AMab91226 
KMT2C CHIP J. Wysocka lab 
(Stanford) 
(Dorighi et al., 2017) 
FLAG Western Blot Sigma F3165-1MG 
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ICAM1 Western Blot Santa Cruz Sc-8439 
AKT (pan) Western Blot Cell Signaling C67E7 
    
 
 
 
Chromatin Immunoprecipitation (CHIP) 
 
CHIP assays were performed as previously described, with the primers listed below. 
 
 
Gene Forward primer Reverse primer 
Rab25 GCTGTCTCTGAAGGTCCTGT AGAGGACGGAAGCTGAGAAC 
CDH1 (5’) CCCCTATCAGTTAGCACCGT AGGTAGGGTAGAGGAGGCTC 
CDH1 (intron 2) GGTTCAAAAGATCCCCTGCG GTCCCCTTTCCTAAGCCACA 
CLDN4 TGGATGGACGGGTTTAGAGG AGGACTCAGAGGGGATCAGT 
OVOL2 TGCCTTAAATCGCGAGTGAG CAGGTAGCGAGCTTGTTGAC 
TP63 GGGGTGGGTGGTAAGGTATT TTGGAAAGAACACTGCCTGC 
ICAM1 ATAAAGGATCACGCGCCCC AGCCCCTCCTTCCCATAAAC 
 
 
 
Bioinformatics and statistics 
 
Retrieval and analysis of the expression levels and EMT scores using publicly available data for 
lung cancer were achieved as follows. Raw expression values (counts) and Z-scores were 
retrieved for LUAD TCGA (provisional, freeze as of June 20,2018) dataset using cBioPortal. EMT 
scores were retrieved from the. For normalization to the IFN-γ transcript levels, raw expression 
data were used (only samples with a detectable (non-zero) counts). Pearson correlation 
coefficients and the corresponding statistical significance values were calculated for the IFN-γ - 
normalized sets of the expression data. For all samples spanning the EMT continuum, the high 
and low subsets were defined as top and bottom quartiles of the scores for each EMT 
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signature. For each gene of interest, the subsets of samples with high and low mRNA expression 
(normalized for IFN-γ transcript levels) were also defined as top and bottom quartiles of the 
corresponding expression range. Statistical significance for the co-occurrence between EMT 
subsets and expression subsets was calculated based on binominal distribution. For NK assays, 
qPCR, and conjugation assaysStudent’s Two Tailed T test was used to compare significance 
 
 
 
Poly(I:C) Viability Assay: 
 
Mcf10aneoT/ +GRHL2/ +gr sg2 were plated at 20,000 cells per well 12 well plates. 48 hrs later, 
2ug of Poly:IC was mixed with 500uL optimem, mixed ,then 3uL Lipofectaime RNAimax was 
added, mixed. Incubated for 15mins. Added to cells that had been washed 1x and refed with 
Optimem. Incubated 37C for 4hrs, washed 2x with normal medium. Incubated 14hrs in normal 
medium, then 50uL of PrestoBlue reagent added to each well. Incubated until good color 
change was observed, then read in a black 96well plate on a platereader using PrestoBlue 
setting. 
RNAseq Experiments 
 
Mcf10aneoT, Mcf10aneoT+GRHL2, Mcf10aneoT+gr sg2 cells were plated in triplicate at equal, 
subconfluent, densities. Cells were treated with 50ug/mL of poly(I:C) for 3hrs, or 400U/mL 
recombinant IFN-γ for 12hrs. Cells were then lysed and processed to make RNA using the 
Qiagen RNeasy Plus Mini kit. RNA was shipped to Genewhiz, where reads were conducted, then 
raw data was shipped to Dr. James Denvir (Marshall) for formatting. Fold induction was 
calculated by averaging triplicate FPKM after poly(I:C) treatment and dividing by triplicate 
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average before ply(I:C) treatment. Genes were then ranked by fold induction. For GSEA 
analysis, GSEA formatted .txt files were created by aligning the absolute expression (FPKM) 
after poly(I:C) stimulation for the triplicate samples from each cell line. This dataset was 
manually cleansed of most genes that were not expressed or had zero reads across all the 
samples. The GSEA formatted .txt file was uploaded to Broad Institute GSEA software and was 
queried against a curated set of “interferon” gene sets downloaded from “msigdatabase.org”. 
These gene sets were curated by downloading all gene sets from msigdatabase.org that were 
found associated with the search term “interferon”. Enrichments with a False Discovery Rate 
FDR<0.25 and a normalized enrichment score NES of >1.2 were considered. 
Extracellular Matrix Switch Experiments 
 
Extracellular matrix was deposited and isolated according to the methods described by (Au - 
Hellewell, Au - Rosini, & Au - Adams, 2017). Generally, cells were plated in multi-well tissue 
culture treated plates until confluent. Cells were washed, then briefly lysed using Ammonium 
hydroxide with agitation. Cellular and medium milieu suspension was then aspirated and wells 
were washed numerous times. This method removes cells, but leaves matrix behind relatively 
intact. Mesenchymal or epithelial derivatives were then plated at subconfluent densities on the 
opposing matrix type. After attachment, these cells were then subjected to an NK assay as 
described above to characterize matrix effects on sensitivity to NK92mi cells. 
 
 
 
Serglycin Overexpression/ Conditioned Media Experiments 
 
The long isoform of Serglycin codes for a cytosolic, non-secreted form. 
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>NM_001321053 (longest isoform, contains signal peptide): 
atgat gcagaagcta 
 
361 ctcaaatgca gtcggcttgt cctggctctt gccctcatcc tggttctgga atcctcagtt 
421 caaggttatc ctacgcggag agccaggtac caatgggtgc gctgcaatcc agacagtaat 
481 tctgcaaact gccttgaaga aaaaggacca atgttcgaac tacttccagg tgaatccaac 
541 aagatccccc gtctgaggac tgaccttttt ccaaagacga gaatccagga cttgaatcgt 
601 atcttcccac tttctgagga ctactctgga tcaggcttcg gctccggctc cggctctgga 
661 tcaggatctg ggagtggctt cctaacggaa atggaacagg attaccaact agtagacgaa 
721 agtgatgctt tccatgacaa ccttaggtct cttgacagga atctgccctc agacagccag 
781 gacttgggtc aacatggatt agaagaggat tttatgttat aa 
457bp 
 
>NP_001307982.1 serglycin isoform 1 precursor [Homo sapiens] 
 
MMQKLLKCSRLVLALALILVLESSVQGYPTRRARYQWVRCNPDSNSANCLEEKGPMFELLPGESNKIPRL 
RTDLFPKTRIQDLNRIFPLSEDYSGSGFGSGSGSGSGSGSGFLTEMEQDYQLVDESDAFHDNLRSLDRNL 
PSDSQDLGQHGLEEDFML 
 
cDNA was generated from HMLE-MSP cells using First Strand Protocol. cDNA was PCR amplified 
using primer sets designed to amplify the Long “L” isoform. 
Primer Sequences: 
 
SRGN-L-F:atgatgcagaagctactcaa 
SRGN-R: ttataacataaaatcctctt 
PCR product was gel extracted and purified, then re-amplified with SRGN primers that 
contained NotI restriction enzyme sites. 
SRGN (w/ NotI sites) Primer sequences: 
 
SRGN-L-F2: tattaaGCGGCCGCCCACC atgatgcagaagctactcaa 
SRGN-R2: tattaaGCGGCCGC ttataacataaaatcctctt 
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After digestion with NotI restriction enzyme, product was PCR purified, then ligated into 
the vector “pMXS-ires-blast-delta-stuffer”. Ligation reaction was transformed into STBL3 
competent E.coli strain. Colonies were selected, midi-prepped and sent for sequencing by 
Sequetech™ (Mountain View, CA) to verify insert. Plasmids were packaged into GP2 cells and 
retrovirus was harvested. Cells were then infected with SRGN retroviral construct and assayed 
for NK killing as described above. 
For Conditioned Media experiments, cell lines expressing high levels of SRGN were 
cultured and allowed to approach confluence. Media was harvested from cells, concentrated, 
and western blotted to verify presence of secreted SRGN. This conditioned media was then 
exchanged for non-SRGN rich media on sensitive cells, and NK assay was conducted to 
determine effects of SRGN conditioned media on sensitive cells. 
GRHL2 Immunohistochemistry Breast Cancer Tissue Microarray 
 
We thank the IU Simon Cancer Center at Indiana University School of Medicine for the 
use of the Tissue Procurement & Distribution Core, which provided Tumor Microarray Service. 
IHC staining was conducted by Dr. Naira Margaryan at WVU. GRHL2 protein staining was scored 
as either 0, +1, +2, or +3. Statistical analysis was conducted using a Student’s Two Tailed T test. 
https://cancer.iu.edu/research-trials/facilities/tissue/policies.php 
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